WO2016099146A1 - 변성 타우린 및 이를 포함하는 대사질환 예방 또는 치료용 약학조성물 - Google Patents
변성 타우린 및 이를 포함하는 대사질환 예방 또는 치료용 약학조성물 Download PDFInfo
- Publication number
- WO2016099146A1 WO2016099146A1 PCT/KR2015/013789 KR2015013789W WO2016099146A1 WO 2016099146 A1 WO2016099146 A1 WO 2016099146A1 KR 2015013789 W KR2015013789 W KR 2015013789W WO 2016099146 A1 WO2016099146 A1 WO 2016099146A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- taurine
- weeks
- modified
- pharmaceutical composition
- denatured
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical class NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 469
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 45
- 208000030159 metabolic disease Diseases 0.000 title claims abstract description 29
- 229960003080 taurine Drugs 0.000 claims abstract description 197
- 239000000203 mixture Substances 0.000 claims abstract description 117
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 130
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 130
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 98
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 94
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 46
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 37
- 235000000346 sugar Nutrition 0.000 claims description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 33
- 208000008589 Obesity Diseases 0.000 claims description 30
- 238000010521 absorption reaction Methods 0.000 claims description 30
- 235000020824 obesity Nutrition 0.000 claims description 30
- 239000002798 polar solvent Substances 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 26
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 26
- 239000008103 glucose Substances 0.000 claims description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims description 24
- 229960003237 betaine Drugs 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 16
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 235000013824 polyphenols Nutrition 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 12
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 claims description 11
- 229930091371 Fructose Natural products 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 10
- 239000005715 Fructose Substances 0.000 claims description 10
- 208000007536 Thrombosis Diseases 0.000 claims description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 238000001237 Raman spectrum Methods 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 7
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 7
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 7
- 230000002792 vascular Effects 0.000 claims description 6
- 238000010792 warming Methods 0.000 claims description 6
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 5
- 150000007946 flavonol Chemical class 0.000 claims description 5
- 235000011957 flavonols Nutrition 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 235000005513 chalcones Nutrition 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 3
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims description 3
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 229930002877 anthocyanin Natural products 0.000 claims description 3
- 235000010208 anthocyanin Nutrition 0.000 claims description 3
- 239000004410 anthocyanin Substances 0.000 claims description 3
- 150000004636 anthocyanins Chemical class 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000011987 flavanols Nutrition 0.000 claims description 3
- 229930003949 flavanone Natural products 0.000 claims description 3
- 150000002207 flavanone derivatives Chemical class 0.000 claims description 3
- 235000011981 flavanones Nutrition 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 206010008138 Cerebral venous thrombosis Diseases 0.000 claims description 2
- ZAQJHHRNXZUBTE-NQXXGFSBSA-N D-ribulose Chemical compound OC[C@@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-NQXXGFSBSA-N 0.000 claims description 2
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000009454 Portal vein thrombosis Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 206010037437 Pulmonary thrombosis Diseases 0.000 claims description 2
- 206010056293 Renal vein occlusion Diseases 0.000 claims description 2
- 150000001330 aldotetroses Chemical class 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 229930015036 aurone Natural products 0.000 claims description 2
- OMUOMODZGKSORV-UVTDQMKNSA-N aurone Chemical compound O1C2=CC=CC=C2C(=O)\C1=C\C1=CC=CC=C1 OMUOMODZGKSORV-UVTDQMKNSA-N 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 claims description 2
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 claims description 2
- 108700003601 dimethylglycine Proteins 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 150000002586 ketotetroses Chemical class 0.000 claims description 2
- 150000002588 ketotrioses Chemical class 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000005772 leucine Nutrition 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 235000006109 methionine Nutrition 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 14
- 230000002785 anti-thrombosis Effects 0.000 abstract description 4
- 235000009200 high fat diet Nutrition 0.000 description 120
- 239000008213 purified water Substances 0.000 description 58
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 51
- 230000000052 comparative effect Effects 0.000 description 46
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 46
- 229960003105 metformin Drugs 0.000 description 46
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 33
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 33
- 229940030275 epigallocatechin gallate Drugs 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 235000021590 normal diet Nutrition 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 25
- 239000000126 substance Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 17
- 239000003925 fat Substances 0.000 description 15
- 210000003486 adipose tissue brown Anatomy 0.000 description 14
- 235000019786 weight gain Nutrition 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 238000010438 heat treatment Methods 0.000 description 13
- 230000004584 weight gain Effects 0.000 description 13
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 12
- 238000009825 accumulation Methods 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 230000037396 body weight Effects 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000007446 glucose tolerance test Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000004930 Fatty Liver Diseases 0.000 description 8
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 238000001069 Raman spectroscopy Methods 0.000 description 8
- 108090000190 Thrombin Proteins 0.000 description 8
- 230000023555 blood coagulation Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000010706 fatty liver disease Diseases 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 229960004072 thrombin Drugs 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 7
- 235000005487 catechin Nutrition 0.000 description 7
- 229950001002 cianidanol Drugs 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000000593 adipose tissue white Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 150000002972 pentoses Chemical class 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 150000002402 hexoses Chemical class 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 108010094028 Prothrombin Proteins 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000004260 weight control Methods 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001434 glomerular Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000012805 animal sample Substances 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- -1 antiplatelets Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- RSDQBPGKMDFRHH-MJVIGCOGSA-N (3s,3as,5ar,9bs)-3,5a,9-trimethyl-3a,4,5,7,8,9b-hexahydro-3h-benzo[g][1]benzofuran-2,6-dione Chemical compound O=C([C@]1(C)CC2)CCC(C)=C1[C@@H]1[C@@H]2[C@H](C)C(=O)O1 RSDQBPGKMDFRHH-MJVIGCOGSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- RSDQBPGKMDFRHH-UHFFFAOYSA-N Taurin Natural products C1CC2(C)C(=O)CCC(C)=C2C2C1C(C)C(=O)O2 RSDQBPGKMDFRHH-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000018548 hypothalamic dysfunction Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005184 irreversible process Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000011661 metabolic syndrome X Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100001095 no nephrotoxicity Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0644—Taurine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a modified taurine and a pharmaceutical composition for preventing or treating metabolic diseases comprising the same as an active ingredient, and more particularly to a pharmaceutical composition for preventing or treating metabolic diseases including a denatured taurine having a physical property different from that of a conventional taurine. It is about.
- Obesity is a disease caused by excessive body fat accumulation due to an imbalance between energy consumption and consumption of the body. It is urgent to prepare measures for mental health as well as physical diseases such as cardiovascular disease, diabetes, hypertension, hyperlipidemia and gallstones. (Kopelman PG. Obesity as medical problem.Nature 404: 635-643, 2000). Especially in Asians, obesity management is more important than other Westerners because the body mass index is at least abdominal obesity and the sensitivity of arterial diseases such as hypertension, diabetes and hyperlipidemia is high.
- Obesity which is present in about 30 to 40% of modern people, is known to be a strong risk factor for high blood pressure, coronary artery disease, type 2 diabetes and various forms of cancer.
- the risk of disease in obese people is 4 times higher in hypertension and 10 times higher in diabetes than normal people, especially obesity and diabetes are closely related to the mechanism of disease.
- taurine is a kind of amino acid, which is a food, rarely contained in plants but widely distributed in animals, and has an inhibitory effect on sympathetic nerves of the brain, which helps stabilize blood pressure and prevent stroke, and atherosclerosis. It is known to inhibit the production of low-density lipoprotein (LDL) cholesterol, which causes angina, myocardial infarction and the like, and is effective in vascular platelet aggregation and adult diseases such as various vascular diseases and dementia.
- LDL low-density lipoprotein
- taurine is difficult to produce useful variants or compositions having therapeutic ability against various diseases, and thus, taurine is generally used as raw materials in amino acid food state.
- the present inventors have completed the development of a pharmaceutical composition for preventing or treating metabolic diseases, including denatured taurine, as a result of intensive efforts.
- an object of the present invention has been made to solve the above problems of the prior art, an object of the present invention to provide a modified taurine and a method for producing the same.
- an object of the present invention is to provide a pharmaceutical composition or food composition for preventing or treating metabolic diseases comprising the modified taurine as an active ingredient.
- taurine is a kind of amino acid which is a food, which is hardly contained in plants, but is widely distributed in animals, and has an inhibitory effect on the sympathetic nerves of the brain to stabilize blood pressure and prevent stroke. It is known to be effective in preventing and producing low-density lipoprotein (LDL) cholesterol, which causes arteriosclerosis, angina pectoris, myocardial infarction, and is effective in adult diseases such as vascular platelet aggregation and various vascular diseases and dementia.
- LDL low-density lipoprotein
- taurine is difficult to produce useful variants or compositions having therapeutic ability against various diseases, and thus, taurine is generally used as raw materials in amino acid food state.
- modified taurine refers to an atypical structure of irregular particles different from the conventional taurine, thereby having different physical properties.
- due to such a difference in physical properties has a significant therapeutic effect on metabolic diseases.
- the denatured taurine has a physical property value of Raman spectrum, FT-IR, TGA, melting point or water solubility is different from taurine.
- the denatured taurine is used as an active ingredient of food or pharmaceutical preparations or used in the synthesis of pharmaceutical preparations, “Taurin, water (H 2 O) and a polar substance having a methyl group (-CH 3 ) in its molecular structure.
- “a is produced by mixing,” taurine, water and molecular structures within a methyl group (-CH 3) the composition "in” water and molecular structure within the polar group-containing material which has been removed a (-CH 3) a polar substance with a " Can be prepared.
- polarity refers to the degree of polarity of the solvent, the usual has a value of 9, ethanol 5.2, methanol 5.1, acetone 5.1, propanol 4, butanol 4.
- the difference in polarity between the solvents may affect the solubility and physical tendency of the particles dissolved in the solvent phase.
- "obesity" is a term that leads to a state having excessive body fat, and when a body fat is 25% or more of body weight, a woman is defined as obesity when 30% or more of body weight.
- Obesity occurs when the amount of calories consumed by food is higher than the amount of calories consumed by the body, and lifestyles such as overeating and lack of exercise are the causes of obesity. This is called simple obesity.
- obesity can occur due to endocrine disorders, hypothalamic dysfunction, and energy metabolism, which is classified as symptomatic obesity. There is also a genetic cause of obesity. Obesity can be measured by height and weight, and calipers can also be used to measure the thickness of skin wrinkles.
- the obesity index which quantifies the degree of obesity, includes the modified broca's method and the body mass index (BMI).
- the ideal weight method is to calculate [height (cm) -100] X0.9 as the ideal weight and display the current weight as a percentage. That is, the obesity degree in the ideal weight method is equal to (measured weight-standard weight) / standard weight x 100%.
- Body mass index is weight divided by height squared. When the current body weight exceeds the ideal body weight by 20%, the case where the BMI is 30 or more is called obesity.
- Obese people may appear fat and may experience shortness of breath and joint pain. It is also accompanied by symptoms such as diabetes and high blood pressure.
- diabetes is a disease caused by abnormalities in the relationship between glucose metabolism and blood glucose control hormone in vivo. Diabetes is classified into insulin dependent diabetes mellitus (type 1 diabetes), insulin independent diabetes mellitus (type 2 diabetes), and malnutrition diabetes mellitus (MRDM). Type 2 diabetes, which accounts for more than 90% of diabetic patients in Korea, is associated with hyperglycemia.
- a metabolic disease characterized by genetic, metabolic and environmental factors has been reported to be caused by decreased insulin secretion of pancreatic beta cells or increased insulin resistance in peripheral tissues. In this regard, the increase in body fat according to obesity shows a decrease in insulin sensitivity, especially the accumulation of abdominal fat is known to be associated with glucose intolerance.
- an insulin sensitivity improving agent for example, thiazolidinedione-based drug and biguanide, which can reduce insulin resistance, as an anti-obesity agent.
- Typical obesity treatments known to date include Xenical TM (Roche Pharmaceuticals, Switzerland), Reductil TM (Abbott, USA), Exolise TM (Atopama, France).
- these drugs have anti-obesity effects by the mechanism of appetite suppression and fat absorption inhibition rather than promoting the burning and decomposition of fats, they cannot fundamentally solve the insulin resistance problem and cannot completely treat diabetes with obesity.
- side effects such as heart disease, respiratory disease, nervous system diseases are reported.
- metabolic syndrome refers to a disease in which various diseases such as diabetes, hypertension, hyperlipidemia, obesity, coronary or atherosclerosis, which occur due to chronic metabolic disorders, occur simultaneously. Reaven GM, Diabetes, 1988, 37: 1595-1607). Metabolic syndrome is characterized by insulin resistance, hypertension, dyslipidemia, and mostly accompanied by overweight or obesity. Metabolic syndrome is also a risk factor for cardiovascular disease and has been reported to be associated with death from all causes. The prevalence of metabolic syndrome is reported to be higher in type 2 diabetic patients than type 1 diabetes, and it is known that mortality increases when the type 2 diabetic patients are accompanied by metabolic syndrome (Bonora E, et al. Diabet Med).
- Korean Laid-Open Patent Publication No. 2008-0059575 discloses a method for treating salts and metabolic diseases of the regulators of PPA, but has been chemically synthesized, which may cause side effects.
- Korean Patent Laid-Open Publication No. 2009-0114093 discloses obesity and metabolic syndrome containing a complex extract of Evodiae Fructus, Imperatae Rhizoma and Cichrus Unshiu Markovich as active ingredients. Metabolic Syndrome or Syndrome X) has disclosed a composition for preventing or treating, Korean Patent Laid-Open No.
- 2010-0956278 includes Yeoju, Cordyceps sinensis, phalanges, baekbaekpi, ear woowoo, brown root, Hwangjeong, Baekchul, Macmundong, cornus, ginseng Disclosed is a composition for the treatment or prevention of diabetes mellitus or diabetic complications using the combined herbal extract as an active ingredient.
- blood coagulation refers to a phenomenon of solidification when blood leaks out of blood vessels.
- blood has various important functions such as transporting and buffering oxygen, nutrients, and waste products, maintaining body temperature, controlling osmotic pressure and ion balance, maintaining moisture, controlling liquid, maintaining and controlling blood pressure, and protecting body. have.
- Normal blood circulation facilitates blood circulation as the blood coagulation reaction system and the thrombolytic reaction system in the body are complementarily regulated.
- the mechanism of the blood coagulation reaction system forms platelet thrombus due to the adhesion of platelets to the blood vessel walls and aggregation.
- the blood coagulation system is activated to form fibrin clots around platelet aggregates.
- the production of fibrin clots causes several thrombin reactions of numerous coagulation factors to activate thrombin, which is involved in fibrin coagulation, to produce fibrin monomers from fibrinogen, which are polymerized by calcium to bind platelets and endothelial cells.
- thrombin activity inhibitors can be used as a prophylactic and therapeutic agent that is very useful for various thrombotic diseases caused by excessive blood clotting.
- thrombotic diseases caused by excessive blood clotting.
- thrombogenic pathway sequential activation of factor XII, XI, IX, and X followed by prothrombin finally activates thrombin.
- Various anticoagulants such as heparin, coumarin, aspirin, urokinase, antiplatelets, and thrombolytic agents have been used for the prevention and treatment of thrombotic diseases.However, they are very expensive and have hemorrhagic side effects, gastrointestinal disorders and hypersensitivity reactions. As a result, its use is limited.
- pharmaceutical composition means a composition to be administered for a specific purpose.
- the pharmaceutical composition of the present invention comprises a denatured taurine and is administered for the prevention or treatment of metabolic diseases, and includes sugars, proteins and pharmaceutically acceptable carriers, excipients or diluents involved therein.
- Said "pharmaceutically acceptable" carrier or excipient means that which has been approved by the governmental regulatory authority, or listed in government or other generally approved pharmacopoeia for use in vertebrates, and more particularly in humans. do.
- compositions comprising modified taurine suitable for parenteral administration may be in the form of suspensions, solutions or emulsions in oily or aqueous carriers, and include formulations such as suspending agents, stabilizers, solubilizers and / or dispersants. can do.
- This form may be sterile and may be liquid. It can be stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria or fungi.
- the pharmaceutical composition comprising denatured taurine may be in sterile powder form for reconstitution with a suitable carrier prior to use.
- the pharmaceutical composition may be in unit-dose form, in ampoules, or in other unit-dose containers, or in multi-dose containers.
- the pharmaceutical composition may be stored in a freeze-dried (freeze-dried) state requiring only the addition of a sterile liquid carrier, for example water for injection just before use.
- a sterile liquid carrier for example water for injection just before use.
- Suitable excipients for pharmaceutical compositions comprising denatured taurine include preservatives, suspending agents, stabilizers, dyes, buffers, antibacterial agents, antifungal agents, and isotonic agents, for example, sugars or sodium chloride.
- the term "stabilizer” refers to a compound optionally used in the pharmaceutical compositions of the present invention to avoid the need for sulfite salts and to increase shelf life.
- stabilizers include antioxidants.
- the pharmaceutical composition may comprise one or more pharmaceutically acceptable carriers.
- the carrier may be a solvent or a dispersion medium.
- pharmaceutically acceptable carriers include water, saline, ethanol, polyols (eg glycerol, propylene glycol and liquid polyethylene glycols), oils, and suitable mixtures thereof.
- Parenteral formulations may be sterile.
- sterilization techniques include filtration through bacterial-suppressive filters, terminal sterilization, incorporation of sterile preparations, irradiation, heating, vacuum drying and freeze drying.
- the pharmaceutical composition according to the present invention is a group consisting of sugars, polyphenols, and amino acids in the "taurine, water, and a composition containing a polar substance having a methyl group (-CH 3 ) in molecular structure" for producing the modified taurine or modified taurine. It can be prepared by adding one or more selected from, characterized in that the sugar is selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
- Food composition in one embodiment of the present invention is used as a food composition for the improvement of metabolic diseases
- the food composition comprising the composition of the present invention as an active ingredient is a variety of foods, for example, beverages, It may be prepared in the form of gum, tea, vitamin complex, powder, granule, tablet, capsule, confectionary, rice cake, bread and the like. Since the food composition of the present invention is configured and improved from the existing food intake which has little toxicity and side effects, it can be used with confidence even when taken for long periods of time.
- the amount may be added at a ratio of 0.1 to 100% of the total weight.
- natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, sucrose and the like, and common sugars such as polysaccharides, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol, and erythritol. can do.
- flavourant examples include natural flavourant (tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.).
- the food composition is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, Stabilizing agents, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, etc. These components may be used independently or in combination
- the ratio of such additives is not so critical, but 100 weight of the composition of the present invention. It is generally selected in the range of 0.1 to 100 parts by weight per part.
- administration means introducing the composition of the invention to the patient in any suitable way, the route of administration of the composition of the invention can be administered via any general route as long as it can reach the desired tissue.
- Oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, intranasal administration, intrapulmonary administration, rectal administration, intranasal administration, intraperitoneal administration, intradural administration can be made, but degeneration of the present invention
- administration is preferably through oral administration or intravenous injection, but is not limited thereto.
- Metabolic disease treatment method of the present invention may include administering the pharmaceutical composition in a pharmaceutically effective amount.
- the effective amount is defined as the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type and formulation of the patient and the age, body weight, general health condition, sex and diet, time of administration, route of administration And various factors, including the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently.
- the modified taurine produced by dissolving taurine on a first polar solvent while warming and adding a second polar solvent, wherein the difference in polarity between the first solvent and the second solvent is 5 or less,
- the modified taurines having an absorption band ratio of 847/891, a 1182/1256 absorption band ratio, and a 1427/1458 absorption band ratio all on positions 847, 891, 1182, 1256, 1427, 1458 cm ⁇ 1 on the Raman spectrum.
- the onset point at which the modified taurine begins to melt provides a modified taurine at 330 degrees to 340 degrees, and provides a modified taurine at a water solubility of 75 to 79 g / L,
- the modified taurine provides a modified taurine having an absorption wavelength at 1650 to 2800 cm ⁇ 1 in infrared spectroscopy (FT-IR) different from taurine, wherein the first polar solvent is water, and the second polar solvent is a methyl group (—CH 3). ), And the second polar solvent provides a modified taurine, which is any one selected from the group consisting of methanol, ethanol, butanol, acetic acid, acetone, propanol, chloroform, and ethyl acetate.
- FT-IR in infrared spectroscopy
- the metabolic disease provides a pharmaceutical composition for preventing or treating metabolic diseases comprising the modified taurine as an active ingredient.
- the metabolic disease provides a pharmaceutical composition, which is diabetes, obesity or thrombotic disease, wherein the thrombotic disease is myocardial infarction, ischemic stroke, hemorrhagic stroke, pulmonary thrombosis, deep vein thrombosis, peripheral vascular obstruction, heart It provides a pharmaceutical composition, at least one selected from the group consisting of arrhythmia thrombosis, portal vein thrombosis, renal vein occlusion, cerebral venous sinus thrombosis, peripheral neuropathy, peripheral vascular disease, nephropathy and central retinal vascular obstruction.
- any one or more selected from the group consisting of amino acids wherein the sugar is ketotriose, aldotriose, ketotetrose, aldotetrose, ribulose, xylose, Ribose, arabinose, mannose, fructose, glucose, sucrose, lactose, maltose, trehal Or at least one selected from the group consisting of cellulose, inulin, and cellulose, wherein the polyphenol is flavanol, flavone, isoflavone, flavonol, flavonol, flavonol It provides a pharmaceutical composition, at least one selected from the group consisting of flavanone, anthocyanin, aurone, chalcone, dihydrochalcone and derivatives thereof, wherein the amino acid is beta Phosphorus, glycine, ornithine, proline, dimethylglycine, aspartic acid, glutamic acid, leucine and methionine are provided in any one or more of the
- the method comprises the steps of: dissolving the taurine on a first polar solvent while warming and adding a second polar solvent to generate a modified taurine, wherein the difference in polarity between the first solvent and the second solvent Is 5 or less, the first polar solvent is water, and the second polar solvent provides a method of producing a modified taurine comprising a methyl group (-CH 3 ).
- the second polar solvent provides a method of producing a modified taurine, wherein the second polar solvent is any one selected from the group consisting of methanol, ethanol, butanol, acetic acid, acetone, propanol, chloroform, and ethyl acetate, and at position 847 on the Raman spectrum.
- onset point provides a method for producing a modified taurine having a 330 degrees to 340 degrees, and provides a method for producing a modified taurine having a water solubility of 75 to 79 g / L, wherein the modified taurine has an infrared spectroscopy (FT-IR) provides a method for producing a modified taurine having an absorption wavelength at a position of 1650 to 2800 cm -1 different from taurine.
- FT-IR infrared spectroscopy
- the present invention provides a food composition for improving and alleviating metabolic diseases comprising the modified taurine.
- heating or heating can be directly heated, or any method capable of heating water, such as a microwave, can be used.
- Elimination of “polar substance with methyl group (-CH 3 ) in molecular structure” can be used in all possible methods such as heating method and separation method.
- Heating method is alcohol boiling point of alcohol (ethanol about 78.4 °C, methanol about 64.7 °C To be removed. In the case of ethanol, it is heated at about 100 ° C. for 1 to 15 minutes based on 100 ml of the mixture.
- a taurine solution in boiling water to heat the water in order to increase the solubility of taurine "modified by the addition of” molecular structure within a methyl group (-CH 3) is a polar material which "the alcohol or acetone
- a composition containing a taurine, water and a polar substance having a methyl group (-CH 3 ) in the molecular structure formed a white semi-solid to produce a taurine (see Fig. 1).
- the white semisolid consists of taurine, water and alcohol (or acetone), and when the alcohol (or acetone) is removed, a "modified taurine" is produced.
- a methyl group (-CH 3) a polar material or a polar solvent comprising or is "a methyl group (-CH 3) an alkyl group (CnH2n + 1) contains a” such as alcohols And the like, and when mixed with an aqueous solution of taurine, it should have an appropriate polarity to form the white semisolid that produces a "modified taurine".
- the white semisolid is a substance formed from taurine, water and a "polar substance with methyl group (-CH 3 ) in molecular structure".
- Examples of the "polar material having a methyl group (-CH 3 ) in the molecular structure" that can be used may include methanol, ethanol, propanol, butanol, acetone, etc., but the alcohol is rapidly reduced in polarity as the carbon number increases. This should be considered as the amount of solids formed is less.
- the amount of the "polar substance having a methyl group (-CH 3 ) in the molecular structure” is less than the above range, there is a concern that the "modified taurine” may not be formed properly.
- the amount of the "polar substance with methyl group (-CH 3 ) in the molecular structure” to be added is not limited as long as the “modified taurine” can be sufficiently produced, but 10 to 3,000 parts by weight based on 100 parts by weight of taurine aqueous solution It is preferable.
- the modified taurine of the present invention and the pharmaceutical composition for preventing or treating metabolic diseases including the same as an active ingredient have an effective effect on anti-triglyceride and antithrombotic effect, and thus are expected to contribute greatly to the prevention and treatment of metabolic syndrome.
- a composition containing water and a polar substance having a methyl group (-CH 3 ) in its molecular structure ” (A: ethanol (alcohol), B: methanol, C: propanol. D: butanol, E: acetone).
- 2 is a Raman spectrum of taurine and denatured taurine, according to one embodiment of the invention.
- FT-IR infrared
- Figure 4 is a SEM analysis of the taurine and denatured taurine according to an embodiment of the present invention.
- TGA graph of taurine and denatured taurine is a TGA graph of taurine and denatured taurine, according to an embodiment of the present invention (A: TGA graph, B: first differential TGA graph).
- A melting point graph
- B analysis report photograph
- 10 to 15 is a graph showing the weight gain of the mouse treated with the pharmaceutical composition of the present invention, in accordance with an embodiment of the present invention.
- 16 to 19 are graphs showing the results of GTT measurement of the mouse treated with the pharmaceutical composition of the present invention according to an embodiment of the present invention.
- 20 to 23 are photographs taken of liver, white adipose tissue (WAT), brown adipose tissue (BAT) and kidney tissue of a mouse treated with the pharmaceutical composition of the present invention according to an embodiment of the present invention.
- WAT white adipose tissue
- BAT brown adipose tissue
- the modified taurine produced by dissolving taurine on a first polar solvent while warming and adding a second polar solvent, wherein the difference in polarity between the first solvent and the second solvent is 5 or less,
- the modified taurines having an absorption band ratio of 847/891, a 1182/1256 absorption band ratio, and a 1427/1458 absorption band ratio all on positions 847, 891, 1182, 1256, 1427, 1458 cm ⁇ 1 on the Raman spectrum.
- a pharmaceutical composition for preventing or treating metabolic diseases including denatured taurine as an active ingredient.
- the method comprises the steps of: dissolving the taurine on a first polar solvent while warming and adding a second polar solvent to generate a modified taurine, wherein the difference in polarity between the first solvent and the second solvent Is 5 or less, the first polar solvent is water, and the second polar solvent provides a method of producing a modified taurine comprising a methyl group (-CH 3 ).
- the present invention provides a food composition for improving and alleviating metabolic diseases comprising the modified taurine.
- Example 1-2 Taualc DT15
- Example 2-1 TauAlc 8.6 * + Ara 2.5 DT16 TauAlc 8.6 + Xyl 3.5 DT20
- Example 2-2-1 TauAlc 8.6 + Ara 1.04 TauAlc 8.6 + Ara 5.2 TauAlc 8.6 + Ara 7.8 TauAlc 8.6 + Xyl 1.04 TauAlc 8.6 + Xyl 5.2 TauAlc 8.6 + Xyl 7.8 TauAlc 4.3 + Rib 2.6 TauAlc 4.3 + Rib 6.5
- Example 2-2-2 TauAlc 8.6 + Ara 1.04 TauAlc 8.6 + Ara 5.2 TauAlc 8.6 + Ara 7.8 TauAlc 8.6 + Xyl 1.04 TauAlc 8.6 + Xyl 5.2 TauAlc 8.6 + Xyl 7.8
- Example 2-3 TauAlc 4.3 + Glu 3.1 TauAlc 4.3 + Glu 7.75 TauAlc 4.3 + Mann
- TauAlc 8.6 means 8.6 g of denatured taurine.
- Tau taurine
- TauAlc modified taurine
- Ara arabinose
- Xyl xylose
- Rib ribose
- Glu glucose
- Mann mannose
- Fruc fructose
- Cat catechin
- Bet betaine
- EGCG Epigallocatechin gallate.
- Taurine (8.6 g) was added to 30 ml of purified water and heated in a microwave for 60 seconds to dissolve. Immediately add 60 ml of alcohol (ethanol (alcohol, alcohol) or methanol, propanol, butanol) or acetone, respectively. Stirring to prepare a composition (FIG. 1) which was a mixture in which a white semisolid was formed.
- alcohol ethanol (alcohol, alcohol) or methanol, propanol, butanol
- acetone acetone
- Taurine (1.72 g) was added to 6 ml of purified water, (2) Taurine (4.3 g) was added to 15 ml of purified water, and (3) Taurine (8.6 g) was added to 28 ml of purified water, and heated in a microwave for 20 to 60 seconds. After dissolution, immediately stir with a rod while adding 12 ml of room temperature ethanol (for stomach (1)), 30 ml of ethanol (for stomach (2)), and 60 ml of ethanol (for stomach (3)). A mixture in which a semisolid of was formed was prepared.
- Solid denatured taurine crystals were prepared in the case of (3) and then dried by a hot air dryer. (Refer to Table 1 for the specific composition ratio of each composition)
- Taurine (4.3 g) was added to 15 ml of purified water or (2) Taurine (8.6 g) was added to 30 ml of purified water, heated in a microwave for 40 to 60 seconds to dissolve, and immediately 30 ml of ethanol (above (1 ) Or 60 ml (in case of (2) above), stir with a rod to prepare a mixture in which a white semi-solid is formed, and then add the previously prepared pentose sugar solution to the mixture, Heated in the microwave for about 3-5 minutes until removed. Purified water was added to this mixed solution, and the total amount was adjusted to 100 ml and used for the experiment. (Refer to Table 1 for the specific composition ratio of each composition)
- Hexose mannose, glucose and fructose
- a fixed amount 3.1 g or 7.75 g
- Taurine 4.3g
- Taurine was newly added to 15 ml of purified water, heated in a microwave oven for about 40 seconds to dissolve, and immediately stirred with a rod while adding 30 ml of ethanol to prepare a mixture having a white semi-solid.
- After adding an aqueous solution of saccharide sugar it was heated in a microwave oven for about 3 minutes and 30 seconds until the alcohol was completely removed, and then purified water was added to adjust the total amount to 100 ml and used in the experiment.
- Taurine (8.6 g) was added to 30 ml of purified water, heated in a microwave oven for about 1 minute 20 seconds, and completely dissolved. Then, 60 ml of ethanol was immediately added and stirred with a rod to prepare a mixture having a white semisolid. Next, 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by addition of catechin (3 g) and betaine (4 g), and then added to the mixture, followed by 5 minutes in a microwave oven. The ethanol was removed by heating. (Refer to Table 1 for the specific composition ratio of each composition)
- Taurine (8.6 g) was added to 30 ml of purified water, heated in a microwave oven for about 1 minute 20 seconds, and completely dissolved. Then, 60 ml of ethanol was immediately added and stirred with a rod to prepare a mixture having a white semisolid. Next, 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by adding EGCG (1.5 g) and betaine (4 g), and then added to the mixture, followed by 5 minutes in a microwave oven. Heated to remove ethanol. (Refer to Table 1 for the specific composition ratio of each composition)
- Taurine (8.6 g) was added to 30 ml of purified water, heated in a microwave oven for about 1 minute 20 seconds, and completely dissolved. Then, 60 ml of ethanol was immediately added and stirred with a rod to prepare a mixture having a white semisolid. Next, 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by adding EGCG (1.5 g), betaine (4 g) and xylose (3.5 g), and then adding to the mixture. Then, ethanol was removed by heating in a microwave for 5 minutes. (Refer to Table 1 for the specific composition ratio of each composition)
- Comparative example 2 Preparation of pharmaceutical composition for the prevention or treatment of metabolic diseases
- Hexose mannose, glucose and fructose
- a fixed amount 3.1 g or 7.75 g
- Taurine 4.3g
- Taurine was newly added to 15 ml of purified water, and dissolved in a microwave oven for about 40 seconds, and the hexasaccharide solution prepared above was mixed. The mixture was heated for about 2 minutes until it boiled in a microwave oven, and purified water was added to adjust the total amount to 100 ml and used for the experiment.
- Taurine (8.6 g) was added to 30 ml of purified water, and heated in a microwave oven for about 1 minute and 20 seconds to completely dissolve to prepare an aqueous solution of taurine.
- 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by adding catechin (3 g) and betaine (4 g), and then added to an aqueous solution of taurine, followed by about 4 minutes in a microwave oven. Heated inside and outside.
- Taurine (8.6 g) was added to 30 ml of purified water, and heated in a microwave oven for about 1 minute and 20 seconds to completely dissolve to prepare an aqueous solution of taurine.
- 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by adding EGCG (1.5 g) and betaine (4 g), and then added to an aqueous solution of taurine, followed by about 4 minutes in a microwave oven. Heated around minutes.
- Taurine (8.6 g) was added to 30 ml of purified water, and heated in a microwave oven for about 1 minute and 20 seconds to completely dissolve to prepare an aqueous solution of taurine.
- 40 ml of purified water was heated at about 100 ° C. for 1 minute using a microwave oven, dissolved by adding EGCG (1.5 g), betaine (4 g) and xylose (3.5 g), and then added to an aqueous taurine solution. Then, it was heated in the microwave for about 4 minutes.
- EGCG epigallocatechin gallate
- betaine betaine
- xylose xylose
- 1650-2800cm taurine in the absorption wavelength in the infrared spectral "taurine-modified" indicates the difference in the infrared spectral absorption wavelength of the first region.
- taurine and "modified taurine” are all ionized (H 3 N + CH 2 CH 2 SO 3 -) the coupling strength between adjacent NH 3 with the same structure or, SO 3 in the decision shows that there is little difference. In other words, there is a difference in the binding strength between molecules in the crystals of ionized taurine and "modified taurine".
- the taurine observed by electron microscope (SEM) has a flaky structure like a crystal column, and the enlarged surface is smooth, but “modified taurine” has a smaller and rounder crystal grain size than the taurine, and the particle size thereof. It was found that the distribution for was very wide and some of the crystals of taurine were mixed. From the enlarged picture of the "modified taurine”, it was confirmed that the "modified taurine” was attached to the surface of the taurine.
- Such shape is formed of small spherical particles of a broad distribution with water and "polar substance with a molecular structure within a methyl group (-CH 3)" in the manufacturing process.
- the "modified taurine” Due to this particle shape, the "modified taurine" has a larger surface area than the taurine of the same mass, so that hydration by adsorption of water in the air is assumed to be easier.
- the average particle size of the taurine was 222.06 ⁇ m
- the median particle size was 192.92 ⁇ m
- the modified taurine had an average particle size of 190.84 ⁇ m
- the median particle size was 122.47 ⁇ m. Therefore, it can be seen that the particle sizes of the taurine and the modified taurine are remarkably different.
- TGA represents the weight loss of the sample with increasing temperature.
- modified taurine there is a slight weight loss from 150 ° C., which is due to the desorption of water molecules from the hydrated SO 3 on the crystal surface, or the thermal decomposition reaction on the surface of very small “modified taurine” particles as shown in the SEM image. It seems to happen a bit faster. Thermal reactivity is appearing faster than taurine because small particles of "modified taurine” increase the area exposed to heat.
- the first decomposition temperature of modified taurine is 359 ° C
- the final decomposition temperature is 396 ° C
- the taurine is decomposed at temperatures of 362 ° C and 394 ° C. This is because the initial pyrolysis occurs first because the modified taurine has a small particle size, but the final decomposition temperature shows higher characteristics.
- the melting point of "denatured taurine” (melting point, onset point basis) was found to be approximately 10 °C higher than the melting point of taurine (335.7 °C each; 336.6 °C respectively) ; and represented by a 337 °C), which Raman or as FT-IR presented on the absorption strength and absorbed wavelengths of the spectrum, determined in the ionized molecules (H 3 N + CH 2 CH 2 SO 3 - a coupling strength between) taurine and There is a difference.
- the water solubility of taurine was 74 g / L, but the water solubility of “denatured taurine” was 77 g / L.
- modified taurine has a physical property value different from that of taurine.
- Antithrombotic (anticoagulant) activity was evaluated according to previously reported methods.
- Sysmex CA-1500 Siemens Healthcare, Germany
- a blood coagulation test automated device was used as a reagent exclusively for Sysmex CA-1500 for PT, aPTT and TT assays.
- PT prothrombin time
- aPTT thromboplastin time
- Activated partial thromboplastin according to the automatic procedure coagulation time (sec) for time)
- TT Thrombin time
- a total of 23-25 ml of blood was collected from a healthy Korean adult man using a blood coagulation test vacutainer (3.2% sodium citrate) and immediately separated by plasma centrifugation at 4 ° C and 2500 rpm for 10 minutes, and then 5 to 6 hours. It was used for the experiment within a fresh state.
- denatured taurine As shown in Table 2, compared with taurine, denatured taurine (TauAlc) increased the PT delay rate when treated alone or in combination with sugar, and when treated with denatured taurine (TauAlc) and sugars together, 5-saccharide (xyl) In the case of the composite form of the oscillation (Xyl) or arabinose (Ara) content of 5.2-7.8g, it was confirmed that the aspirin (Asp) had a PT delay rate and TT delay rate equal to or higher than 7.5 mg / dL. .
- denatured taurine As shown in Table 3, compared to taurine, denatured taurine (TauAlc) increased the TT delay rate when treated alone or in combination with sugar, and when treated with denatured taurine (TauAlc) and sugar together, sugar (Ribose (Rib) ) Or glucose (Gluc) content of 2.6 ⁇ 7.75 g of the composite form was confirmed that the aspirin (Asp) 7.5 mg / dL comparable or higher than the TT delay rate.
- denatured taurine As shown in Table 4, compared with taurine, denatured taurine (TauAlc) increased the TT delay rate when treated alone or in combination with sugar, and when treated with denatured taurine (TauAlc) and sugar together, sugar (Mannose (Mann) ) Or fructose) was found to have a TT retardation rate of 7.5 mg / dL or more of aspirin (Asp) in the case of a composite form of 7.75 g.
- mice Eight-week-old male mice (C57BL / 6) (obtained from KOATEC) were evaluated for anti-diabetic efficacy candidates using the GTT (Glucose Tolerance Test) method, which is a representative diabetes diagnostic test method.
- GTT Glucose Tolerance Test
- mice The breeding environmental conditions of the mice were set to 22 ⁇ 2 °C, relative humidity 55-60%, lit 12 hours a day, turned off 12 hours. Five rats were assigned to each group, and male mice were vigorously contested and randomly divided into groups from one mother.
- Feed was fed for 10 weeks without restriction (60% of calories from fat; research diet inc., New Brunswick, NJ) and water.
- the samples prepared in Examples 1-2 (3), 2-1, 2-4-1, 2-4-2 and 2-5 were mixed and supplied without restriction.
- metformin (M-072, Sigma) 250 mg / kg was used as a positive control, and Comparative Examples 1-1, 2-3-2, 2-5-1, 2-5-2 and 2 as control. Samples prepared at -6 were used.
- the samples prepared in Examples 2-4-1, 2-4-2, and 2-5 were set to the amount that the adult male (60 kg) takes 3 days and the dose of mice (12 times / kg, US) Animal samples were prepared. That is, the amount that adult male (60 kg) takes 3 days is 180 days / kg, which is 15 days / kg of mouse. Therefore, the average weight of the mouse is about 20g, corresponding to 750 matched mice (20g). Therefore, one mouse was allowed to take 1/750 of the prepared sample per day.
- the samples prepared in Examples 1-2 (3) and 2-1 were set to the amount taken by an adult male (60kg) for 2 days, and the dose of mice (12 times / kg, refer to US NIH guidance data).
- the amount that an adult male (60 kg) takes 2 days is 120 days / kg and this is 10 days / kg of mouse. Therefore, the average weight of the mouse is about 20g corresponds to 500 days / mouse (20g). Therefore, one mouse was allowed to take 1/500 of the prepared sample per day.
- GTT glucose tolerance test
- the mice were fasted for 8 hours before the experiment. After that, blood was collected from the tail vein, and the initial blood glucose was measured by a blood glucose meter (AUTO-CHEK, Diatec Korea), and then the concentration of glucose in the abdominal cavity of the mouse was 1 g / kg. After administration, blood glucose was measured at 30, 60, 90 and 120 minutes (mean of 5 animals in each group).
- Blood biochemical tests included insulin (AKRIN-011T, Shibayagi, Japan), glucose (AM202, Asan, Korea), triglycerides (AM157, Asan), total cholesterol (AM202, Asan), AST and ALT ( AM101, Asan Pharmaceuticals) were analyzed using enzymatic assay kits.
- mice were sacrificed by cervical distal bone to obtain serum at 10 weeks of high fat diet.
- liver, white adipose tissue (WAT), brown adipose tissue (BAT) and kidney were fixed with formalin (50-00-0, Junsei, Japan), and the remaining organs were stored at -70 ° C.
- Blood collected from the heart was coagulated to obtain serum, and then stored at -70 ° C.
- Tissue samples were prepared and mounted with glycerin gel mounting media (SP15-100, Fisher Scientific, USA), covered with a cover glass and observed under a microscope (IX71, OLYMPUS, Japan), and tissue was photographed with a digital camera built into the microscope.
- glycerin gel mounting media SP15-100, Fisher Scientific, USA
- Body weight, weight gain and weight gain T-TEST results are shown in FIGS. 10 to 15 and Tables 5 to 22 below.
- DT16 to which denatured taurine (TauAlc) and arabinose (Ara) were administered showed significant weight gain inhibitory effect compared to high fat diet (HFD) alone at 8 weeks after administration of high fat diet (HFD).
- HFD high fat diet
- DT18 administered with taurine (Tau) and arabinose (Ara) did not show a significant weight increase inhibitory effect.
- DT20 administered denatured taurine (TauAlc) and xylose (Ara) and DT21 administered taurine (Tau) and xylose (Ara) were 8 weeks after high-fat diet (HFD) administration. It was confirmed that the high fat diet (HFD) alone showed a significant weight increase inhibitory effect.
- DT7 to which denatured taurine (TauAlc), catechin (Cat) and betaine (Bet) were administered was significantly compared to high fat diet (HFD) 8 weeks after high fat diet (HFD) administration.
- HFD high fat diet
- DT11 administered with taurine (Tau), catechin (Cat) and betaine (Bet) did not show a significant weight increase inhibitory effect.
- the DT7 administration group was determined to have a significantly greater weight control effect than the DT11 administration group.
- DT10 to which denatured taurine (TauAlc), epigallocatechin gallate (EGCG) and betaine (Bet) was administered was 8 weeks after high-fat diet (HFD) alone, high-fat diet (HFD) alone It showed significant weight-inhibitory effects compared to, but DT14 administered with taurine (Tau), epigallocatechin gallate (EGCG) and betaine (Bet) did not show significant weight-inhibitory effects. I could confirm it.
- the DT10 administration group was determined to have a significantly greater weight control effect than the DT14 administration group.
- DT4 to which denatured taurine (TauAlc), epigallocatechin gallate (EGCG), betaine (Bet) and xylose (Xyl) was administered was 8 weeks after high-fat diet (HFD) administration. Compared with high fat diet (HFD) alone, it showed a significant weight gain inhibitory effect, but taurine (Tau), epigallocatechin gallate (EGCG), betaine (Bet) and xylose (Xyl) were administered. One DT6 did not show a significant weight increase inhibitory effect. In addition, the DT4 administration group was determined to have a significantly greater weight control effect than the DT6 administration group.
- mice in the DT15 and DT19 groups were significantly better in blood glucose control than the HFD-only group, and similarly, the blood glucose control ability was similar between DT15 and DT19.
- mice in the DT16 group were significantly better in blood glucose control than the HFD-only group, maintaining the blood glucose level of normal mice.
- the DT16 group was more effective than the DT18 group Excellent and fasting blood glucose levels were found to be significantly lower.
- mice in the DT20 and DT21 groups were significantly better in blood glucose control than the HFD alone group, and there was no significant difference between the DT20 and DT21 groups, but the DT20 group showed better effects than the DT21 group. I could see that.
- mice in the DT4 group were significantly better in glycemic control than the HFD alone group, but the mice in the DT6 group were low in blood glucose control.
- Triglyceride, AST and ALT test results and the T-test results are shown in Tables 31 to 40 below.
- DT15 denatured taurine shows similar or better levels of triglyceride, AST and ALT levels than normal mice, and significantly lower triglyceride levels than DT19 (taurine), AST and ALT levels were also low.
- DT16 denatured taurine + arabinose
- DT18 taurine + arabinose
- HFD high-fat diet
- DT16 also showed lower triglyceride levels than normal diet (RD).
- DT20 denatured taurine + xylose
- DT18 taurine + xylose
- HFD high-fat diet
- DT20 and DT21 showed lower triglyceride levels than normal diet (RD).
- DT7 denatured taurine + catechin + betaine shows similar levels of AST and ALT as normal diet (RD), and is lower than AST and ALT of high fat diet (HFD). The value is shown. DT7 also showed lower triglyceride levels than normal diet (RD).
- DT4 denatured taurine + ECCG + betaine + xylose shows similar levels of AST and ALT as normal diet (RD), and AST and high fat diet (HFD) The value was significantly smaller than ALT. DT4 also showed lower triglyceride levels than normal diet (RD).
- FIGS. 20 to 23 The test results of liver, white adipose tissue (WAT), brown adipose tissue (BAT) and kidney tissue of experimental mice are shown in FIGS. 20 to 23.
- the modified taurine of the present invention and the pharmaceutical composition for preventing or treating metabolic diseases including the same as an active ingredient have an effective effect on anti-triglyceride and antithrombotic effect, and thus are expected to contribute greatly to the prevention and treatment of metabolic syndrome.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
Abstract
Description
실시예 1-2 | TauAlc | DT15 |
실시예 2-1 | TauAlc 8.6*+Ara 2.5 | DT16 |
TauAlc 8.6+Xyl 3.5 | DT20 | |
실시예 2-2-1 | TauAlc 8.6+Ara 1.04 | |
TauAlc 8.6+Ara 5.2 | ||
TauAlc 8.6+Ara 7.8 | ||
TauAlc 8.6+Xyl 1.04 | ||
TauAlc 8.6+Xyl 5.2 | ||
TauAlc 8.6+Xyl 7.8 | ||
TauAlc 4.3+Rib 2.6 | ||
TauAlc 4.3+Rib 6.5 | ||
실시예 2-2-2 | TauAlc 8.6+Ara 1.04 | |
TauAlc 8.6+Ara 5.2 | ||
TauAlc 8.6+Ara 7.8 | ||
TauAlc 8.6+Xyl 1.04 | ||
TauAlc 8.6+Xyl 5.2 | ||
TauAlc 8.6+Xyl 7.8 | ||
실시예 2-3 | TauAlc 4.3+Glu 3.1 | |
TauAlc 4.3+Glu 7.75 | ||
TauAlc 4.3+Mann 3.1 | ||
TauAlc 4.3+Mann 7.75 | ||
TauAlc 4.3+Fruc 7.75 | ||
실시예 2-4-1 | TauAlc 8.6+Cat 3+Bet 4 | DT7 |
실시예 2-4-2 | TauAlc 8.6+EGCG 1.5+Bet 4 | DT10 |
실시예 2-5 | TauAlc 8.6+EGCG 1.5+Bet 4+Xyl 3.5 | DT4 |
비교예 1 | Tau** | DT19 |
비교예 2-1 | Ara 1.04 | |
Ara 5.2 | ||
Ara 7.8 | ||
Xyl 1.04 | ||
Xyl 5.2 | ||
Xyl 7.8 | ||
Rib 5.2 | ||
Rib 10.4 | ||
비교예 2-2 | Glu 6.2 | |
Glu 12.4 | ||
Mann 3.1 | ||
Mann 6.2 | ||
Mann 12.4 | ||
Fruc 6.2 | ||
Fruc 12.4 | ||
비교예 2-3-1 | Tau 8.6+Ara 1.04 | |
Tau 8.6+Ara 5.2 | ||
Tau 8.6+Ara 7.8 | ||
Tau 8.6+Xyl 1.04 | ||
Tau 8.6+Xyl 5.2 | ||
Tau 8.6+Xyl 7.8 | ||
Tau 4.3+Rib 2.6 | ||
Tau 4.3+Rib 6.5 | ||
비교예 2-3-2 | Tau 8.6+Ara 2.5 | DT18 |
Tau 8.6+Xyl 3.5 | DT21 | |
비교예 2-4 | Tau 4.3+Glu 3.1 | |
Tau 4.3+Glu 7.75 | ||
Tau 4.3+Mann 3.1 | ||
Tau 4.3+Mann 7.75 | ||
Tau 4.3+Fruc 7.75 | ||
비교예 2-5-1 | Tau 8.6+Cat 3+Bet 4 | DT11 |
비교예 2-5-2 | Tau 8.6+EGCG 1.5+Bet 4 | DT14 |
비교예 2-6 | Tau 8.6+EGCG 1.5+Bet 4+Xyl 3.5 | DT6 |
시험물질 (g/dL) | N | PT | aPTT | TT | ||||
평균 | 표준 편차 | 평균 | 표준 편차 | 평균 | 표준 편차 | |||
대조구 | 정제수 | 3 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
대조구 | Asp 7.5mg/㎖ | 3 | 9.90 | 0.24 | 7.31 | 0.79 | 13.59 | 1.79 |
비교예 2-1 | Ara 1.04 | 3 | 0.56 | 0.98 | 2.51 | 0.92 | 2.09 | 0.53 |
Ara 5.2 | 3 | 5.93 | 1.47 | 3.72 | 1.76 | 13.40 | 1.01 | |
Ara 7.8 | 3 | 9.60 | 1.29 | 6.39 | 1.90 | 22.92 | 1.22 | |
Xyl 1.04 | 3 | 0.85 | 0.85 | 1.23 | 1.35 | 2.68 | 0.02 | |
Xyl 5.2 | 3 | 4.52 | 1.29 | 5.70 | 0.91 | 14.59 | 1.49 | |
Xyl 7.8 | 3 | 7.63 | 1.47 | 6.47 | 2.12 | 24.41 | 1.22 | |
비교예1-2 | Tau 1.72 | 3 | 0.00 | 0.85 | -2.41 | 0.81 | 3.58 | 0.92 |
Tau 4.3 | 3 | 0.56 | 0.98 | -4.35 | 1.17 | 9.83 | 1.63 | |
Tau 8.6 | 3 | 4.80 | 1.29 | -4.01 | 0.33 | 21.13 | 0.55 | |
비교예2-3-1 | Tau 8.6+Ara 1.04 | 3 | 4.80 | 0.49 | -4.01 | 0.41 | 22.03 | 0.69 |
Tau 8.6+Ara 5.2 | 3 | 9.04 | 1.29 | -1.06 | 0.67 | 33.64 | 2.10 | |
Tau 8.6+Ara 7.8 | 3 | 12.71 | 1.47 | 0.83 | 1.35 | 42.57 | 1.38 | |
Tau 8.6+Xyl 1.04 | 3 | 4.80 | 0.98 | -3.73 | 0.85 | 24.11 | 0.22 | |
Tau 8.6+Xyl 5.2 | 3 | 8.76 | 0.49 | 0.47 | 1.97 | 36.32 | 1.33 | |
Tau 8.6+Xyl 7.8 | 3 | 12.99 | 1.29 | 1.73 | 1.95 | 45.54 | 0.77 | |
실시예 1-2 | TauAlc 1.72 | 3 | 2.27 | 1.78 | -1.19 | 1.26 | 4.06 | 0.46 |
TauAlc 4.3 | 3 | 2.26 | 1.76 | -2.57 | 0.42 | 9.39 | 1.11 | |
TauAlc 8.6 | 3 | 4.82 | 1.32 | -2.73 | 1.69 | 20.64 | 1.25 | |
실시예2-2-1 | TauAlc 8.6+Ara 1.04 | 3 | 7.66 | 2.99 | 0.18 | 1.56 | 21.25 | 0.59 |
TauAlc 8.6+Ara 5.2 | 3 | 12.46 | 0.43 | 2.40 | 0.54 | 32.21 | 1.68 | |
TauAlc 8.6+Ara 7.8 | 3 | 16.71 | 0.54 | 4.03 | 1.08 | 40.35 | 3.18 | |
TauAlc 8.6+Xyl 1.04 | 3 | 6.80 | 0.03 | -0.67 | 1.93 | 25.64 | 1.75 | |
TauAlc 8.6+Xyl 5.2 | 3 | 11.05 | 0.05 | 1.11 | 0.30 | 35.33 | 1.43 | |
TauAlc 8.6+Xyl 7.8 | 3 | 14.73 | 0.56 | 4.89 | 0.50 | 43.77 | 2.47 | |
실시예2-2-2 | TauAlc 8.6+Ara 1.04 | 3 | 4.25 | 0.87 | -1.52 | 3.58 | 21.58 | 1.26 |
TauAlc 8.6+Ara 5.2 | 3 | 11.62 | 0.52 | 1.04 | 1.70 | 37.19 | 0.52 | |
TauAlc 8.6+Ara 7.8 | 3 | 13.60 | 0.07 | 1.46 | 1.06 | 41.92 | 3.15 | |
TauAlc 8.6+Xyl 1.04 | 3 | 5.95 | 0.88 | -0.85 | 0.64 | 27.86 | 3.52 | |
TauAlc 8.6+Xyl 5.2 | 3 | 10.20 | 0.85 | 1.46 | 1.00 | 36.27 | 1.23 | |
TauAlc 8.6+Xyl 7.8 | 3 | 13.88 | 0.56 | 3.18 | 1.80 | 45.01 | 1.88 |
시험물질 (g/dL) | N | PT | aPTT | *TT | ||||
평균 | 표준 편차 | 평균 | 표준 편차 | 평균 | 표준 편차 | |||
대조구 | 정제수 | 3 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
대조구 | Asp 7.5mg/㎖ | 3 | 17.51 | 2.72 | 16.28 | 2.04 | 20.96 | 5.10 |
비교예 2-1 | Rib 5.2 | 3 | 8.47 | 2.24 | 9.17 | 1.42 | 23.15 | 8.20 |
Rib 10.4 | 3 | 14.97 | 2.59 | 12.46 | 3.16 | 52.50 | 7.63 | |
비교예 2-2 | Gluc 6.2 | 3 | 1.69 | 0.85 | 2.22 | 0.73 | 16.24 | 3.09 |
Gluc 12.4 | 3 | 2.26 | 1.29 | 2.89 | 0.78 | 27.82 | 7.79 | |
비교예 1-2 | Tau 4.3 | 3 | 1.69 | 0.85 | -0.29 | 1.17 | 11.18 | 5.29 |
비교예2-3-1 | Tau 4.3+Rib 2.6 | 3 | 4.80 | 0.49 | 1.65 | 1.03 | 20.57 | 6.88 |
Tau 4.3+Rib 6.5 | 3 | 10.73 | 0.49 | 4.25 | 0.98 | 34.61 | 6.87 | |
비교예 2-4 | Tau 4.3+Gluc 3.1 | 3 | 0.00 | 0.85 | -1.25 | 1.61 | 19.23 | 3.82 |
Tau 4.3+Gluc 7.75 | 3 | 1.98 | 1.29 | -1.54 | 1.09 | 30.30 | 4.29 | |
실시예 1-2 | TauAlc 4.3 | 3 | 0.85 | 0.85 | -2.03 | 2.03 | 12.49 | 7.15 |
실시예2-2-1 | TauAlc 4.3+ Rib 2.6 | 3 | 5.37 | 0.49 | 2.61 | 2.79 | 21.84 | 6.34 |
TauAlc 4.3+ Rib 6.5 | 3 | 11.02 | 0.85 | 3.96 | 0.78 | 35.88 | 6.33 | |
실시예2-3 | TauAlc 4.3+ Gluc 3.1 | 3 | 0.85 | 0.85 | -1.06 | 1.18 | 24.16 | 4.40 |
TauAlc 4.3+ Gluc 7.75 | 3 | 3.11 | 2.13 | -0.56 | 2.30 | 41.80 | 15.69 |
시험물질 (g/dL) | N | PT | aPTT | TT | ||||
평균 | 표준 편차 | 평균 | 표준 편차 | 평균 | 표준 편차 | |||
대조구 | 정제수 | 3 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
대조구 | Asp 7.5mg/㎖ | 3 | 26.02 | 1.41 | 29.82 | 1.78 | 23.95 | 2.18 |
비교예 2-2 | Mann 3.1 | 3 | 2.71 | 0.94 | 0.65 | 3.67 | 11.67 | 1.56 |
Mann 6.2 | 3 | 5.96 | 3.29 | 1.24 | 4.22 | 22.74 | 4.59 | |
Mann 12.4 | 3 | 13.55 | 2.05 | 7.98 | 3.07 | 47.87 | 4.27 | |
Fruc 6.2 | 3 | 0.54 | 0.94 | -0.20 | 3.04 | 13.19 | 1.43 | |
Fruc 12.4 | 3 | 0.54 | 0.94 | 0.58 | 4.29 | 30.07 | 1.65 | |
비교예 1-2 | Tau 4.3 | 3 | -3.79 | 2.35 | -5.50 | 3.82 | 9.51 | 2.10 |
비교예 2-4 | Tau 4.3+ Mann 3.1 | 3 | -1.08 | 2.35 | -3.14 | 3.83 | 17.48 | 0.78 |
Tau 4.3+ Mann 7.75 | 3 | 6.23 | 1.69 | -0.02 | 3.64 | 31.60 | 2.08 | |
Tau 4.3+ Fruc 7.75 | 3 | 0.00 | 0.81 | -3.49 | 2.86 | 30.39 | 2.81 | |
실시예 1-2 | TauAlc 4.3 | 3 | -3.79 | 2.35 | -5.45 | 2.18 | 10.12 | 0.78 |
실시예2-3 | TauAlc 4.3+ Mann 3.1 | 3 | 0.54 | 1.88 | -2.65 | 3.33 | 18.74 | 3.05 |
TauAlc 4.3+ Mann 7.75 | 2* | 5.69 | 0.00 | 1.03 | 0.37 | 34.59 | 2.63 | |
TauAlc 4.3+ Fruc 7.75 | 3 | -1.36 | 0.47 | -3.50 | 2.58 | 29.78 | 2.97 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 17.80 | 19.36 | 21.48 | 22.44 | 23.56 | 24.32 | 24.78 | 25.74 | 26.18 |
편차 | 0.17 | 0.35 | 0.54 | 0.56 | 0.54 | 0.57 | 0.66 | 0.78 | 0.81 | ||
대조구 | 고지방식이(HFD) | 평균 | 20.68 | 23.58 | 24.87 | 26.50 | 28.16 | 30.12 | 31.85 | 33.04 | 35.96 |
편차 | 0.29 | 0.54 | 0.53 | 0.57 | 0.62 | 0.68 | 0.52 | 0.47 | 0.42 | ||
실시예 1-2(3) | DT15 (TauAlc) | 평균 | 17.65 | 20.30 | 22.05 | 23.93 | 25.18 | 26.03 | 27.90 | 28.75 | 29.23 |
편차 | 0.16 | 0.17 | 0.27 | 0.26 | 0.27 | 0.22 | 0.41 | 0.38 | 0.37 | ||
비교예 1-1 | DT19 (Tau) | 평균 | 19.26 | 21.46 | 23.62 | 24.60 | 25.78 | 27.38 | 27.20 | 28.06 | 28.78 |
편차 | 0.28 | 0.35 | 0.59 | 0.66 | 0.63 | 0.77 | 0.84 | 0.97 | 1.10 | ||
대조구 | Metformin(MET) | 평균 | 19.30 | 21.00 | 22.78 | 23.84 | 25.18 | 25.72 | 26.34 | 27.52 | 28.20 |
편차 | 0.62 | 0.72 | 0.99 | 0.97 | 1.16 | 1.04 | 1.07 | 1.24 | 1.37 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 1.56 | 3.68 | 4.64 | 5.76 | 6.52 | 6.98 | 7.94 | 8.38 |
편차 | 0.24 | 0.45 | 0.48 | 0.44 | 0.51 | 0.59 | 0.68 | 0.73 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.90 | 4.19 | 5.82 | 7.48 | 9.44 | 11.17 | 12.36 | 15.28 |
편차 | 0.52 | 0.50 | 0.51 | 0.49 | 0.52 | 0.36 | 0.35 | 0.29 | ||
실시예 1-2(3) | DT15 (TauAlc) | 평균 | 2.65 | 4.40 | 6.28 | 7.53 | 8.38 | 10.25 | 11.10 | 11.58 |
편차 | 0.25 | 0.28 | 0.34 | 0.40 | 0.36 | 0.52 | 0.46 | 0.40 | ||
비교예 1-1 | DT19 (Tau) | 평균 | 2.20 | 4.36 | 5.34 | 6.52 | 8.12 | 7.94 | 8.80 | 9.52 |
편차 | 0.10 | 0.73 | 0.81 | 0.74 | 0.91 | 0.91 | 1.06 | 1.12 | ||
대조구 | Metformin(MET) | 평균 | 1.70 | 3.48 | 4.54 | 5.88 | 6.42 | 7.04 | 8.22 | 8.90 |
편차 | 0.30 | 1.10 | 0.99 | 1.19 | 1.11 | 1.14 | 1.29 | 1.44 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT15 | 0.7736 | 0.8052 | 0.6050 | 0.9579 | 0.2443 | 0.1925 | 0.0656 | 0.0000 |
HFD vs DT19 | 0.3663 | 0.8499 | 0.6119 | 0.2908 | 0.1971 | 0.0016 | 0.0013 | 0.0000 |
DT15 vs DT19 | 0.1145 | 0.9645 | 0.3648 | 0.3044 | 0.8198 | 0.0801 | 0.1116 | 0.1623 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 17.80 | 19.36 | 21.48 | 22.44 | 23.56 | 24.32 | 24.78 | 25.74 | 26.18 |
편차 | 0.17 | 0.35 | 0.54 | 0.56 | 0.54 | 0.57 | 0.66 | 0.78 | 0.81 | ||
대조구 | 고지방식이(HFD) | 평균 | 20.68 | 23.58 | 24.87 | 26.50 | 28.16 | 30.12 | 31.85 | 33.04 | 35.96 |
편차 | 0.29 | 0.54 | 0.53 | 0.57 | 0.62 | 0.68 | 0.52 | 0.47 | 0.42 | ||
실시예 2-1 | DT16 (TauAlc 8.6+Ara 2.5) | 평균 | 19.88 | 22.16 | 23.94 | 25.02 | 26.44 | 27.34 | 27.92 | 28.50 | 30.62 |
편차 | 0.32 | 0.32 | 0.43 | 0.53 | 0.75 | 0.71 | 0.79 | 0.74 | 0.84 | ||
비교예2-3-2 | DT 18(Tau 8.6+Ara 2.5) | 평균 | 20.20 | 22.29 | 23.47 | 25.17 | 26.70 | 27.67 | 29.03 | 30.77 | 32.03 |
편차 | 0.50 | 0.55 | 0.58 | 0.97 | 1.30 | 1.58 | 1.96 | 2.11 | 2.72 | ||
대조구 | Metformin(MET) | 평균 | 19.30 | 21.00 | 22.78 | 23.84 | 25.18 | 25.72 | 26.34 | 27.52 | 28.20 |
편차 | 0.62 | 0.72 | 0.99 | 0.97 | 1.16 | 1.04 | 1.07 | 1.24 | 1.37 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 1.56 | 3.68 | 4.64 | 5.76 | 6.52 | 6.98 | 7.94 | 8.38 |
편차 | 0.24 | 0.45 | 0.48 | 0.44 | 0.51 | 0.59 | 0.68 | 0.73 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.90 | 4.19 | 5.82 | 7.48 | 9.44 | 11.17 | 12.36 | 15.28 |
편차 | 0.52 | 0.50 | 0.51 | 0.49 | 0.52 | 0.36 | 0.35 | 0.29 | ||
실시예 2-1 | DT16 (TauAlc 8.6+Ara 2.5) | 평균 | 2.28 | 4.06 | 5.14 | 6.56 | 7.46 | 8.04 | 8.62 | 10.74 |
편차 | 0.29 | 0.71 | 0.75 | 1.00 | 1.00 | 1.05 | 1.02 | 1.15 | ||
비교예2-3-2 | DT 18(Tau 8.6+Ara 2.5) | 평균 | 2.09 | 3.27 | 4.97 | 6.50 | 7.47 | 8.83 | 10.57 | 11.83 |
편차 | 0.16 | 0.91 | 1.42 | 1.77 | 2.02 | 2.40 | 2.54 | 3.15 | ||
대조구 | Metformin(MET) | 평균 | 1.70 | 3.48 | 4.54 | 5.88 | 6.42 | 7.04 | 8.22 | 8.90 |
편차 | 0.30 | 1.10 | 0.99 | 1.19 | 1.11 | 1.14 | 1.29 | 1.44 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT16 | 0.4351 | 0.8839 | 0.4636 | 0.3673 | 0.0722 | 0.0036 | 0.0008 | 0.0002 |
HFD vs DT18 | 0.4222 | 0.3970 | 0.4895 | 0.4556 | 0.1827 | 0.1121 | 0.2258 | 0.0582 |
DT16 vs DT18 | 0.6482 | 0.5201 | 0.9100 | 0.9753 | 0.9974 | 0.7355 | 0.4307 | 0.7065 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 17.80 | 19.36 | 21.48 | 22.44 | 23.56 | 24.32 | 24.78 | 25.74 | 26.18 |
편차 | 0.17 | 0.35 | 0.54 | 0.56 | 0.54 | 0.57 | 0.66 | 0.78 | 0.81 | ||
대조구 | 고지방식이(HFD) | 평균 | 20.68 | 23.58 | 24.87 | 26.50 | 28.16 | 30.12 | 31.85 | 33.04 | 35.96 |
편차 | 0.29 | 0.54 | 0.53 | 0.57 | 0.62 | 0.68 | 0.52 | 0.47 | 0.42 | ||
실시예 2-1 | DT20 (TauAlc 8.6+Xyl 3.5) | 평균 | 19.56 | 22.76 | 24.02 | 25.38 | 27.38 | 28.40 | 28.86 | 30.28 | 32.28 |
편차 | 0.49 | 0.67 | 0.48 | 0.76 | 0.77 | 0.88 | 1.05 | 0.94 | 0.96 | ||
비교예2-3-2 | DT 21(Tau 8.6+Xyl 3.5) | 평균 | 19.64 | 21.64 | 24.22 | 26.16 | 27.28 | 27.22 | 29.04 | 30.02 | 31.74 |
편차 | 0.15 | 0.15 | 0.10 | 0.32 | 0.27 | 0.27 | 0.16 | 0.34 | 0.81 | ||
대조구 | Metformin(MET) | 평균 | 19.30 | 21.00 | 22.78 | 23.84 | 25.18 | 25.72 | 26.34 | 27.52 | 28.20 |
편차 | 0.62 | 0.72 | 0.99 | 0.97 | 1.16 | 1.04 | 1.07 | 1.24 | 1.37 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 1.56 | 3.68 | 4.64 | 5.76 | 6.52 | 6.98 | 7.94 | 8.38 |
편차 | 0.24 | 0.45 | 0.48 | 0.44 | 0.51 | 0.59 | 0.68 | 0.73 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.90 | 4.19 | 5.82 | 7.48 | 9.44 | 11.17 | 12.36 | 15.28 |
편차 | 0.52 | 0.50 | 0.51 | 0.49 | 0.52 | 0.36 | 0.35 | 0.29 | ||
실시예 2-1 | DT20 (TauAlc 8.6+Xyl 3.5) | 평균 | 3.20 | 4.46 | 5.82 | 7.82 | 8.84 | 9.30 | 10.72 | 12.72 |
편차 | 0.36 | 0.72 | 0.56 | 1.11 | 0.85 | 1.01 | 1.02 | 1.13 | ||
비교예2-3-2 | DT 21(Tau 8.6+Xyl 3.5) | 평균 | 2.00 | 4.58 | 6.52 | 7.64 | 7.58 | 9.40 | 10.38 | 12.10 |
편차 | 0.14 | 0.14 | 0.41 | 0.41 | 0.32 | 0.27 | 0.41 | 0.95 | ||
대조구 | Metformin(MET) | 평균 | 1.70 | 3.48 | 4.54 | 5.88 | 6.42 | 7.04 | 8.22 | 8.90 |
편차 | 0.30 | 1.10 | 0.99 | 1.19 | 1.11 | 1.14 | 1.29 | 1.44 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT20 | 0.7082 | 0.7623 | 1.0000 | 0.7485 | 0.5373 | 0.0498 | 0.0774 | 0.0118 |
HFD vs DT21 | 0.2521 | 0.6032 | 0.3923 | 0.8377 | 0.0330 | 0.0072 | 0.0042 | 0.0012 |
DT20 vs DT21 | 0.0154 | 0.8733 | 0.3409 | 0.8829 | 0.2028 | 0.9263 | 0.7659 | 0.6847 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 22.894 | 23.692 | 24.138 | 24.285 | 24.507 | 24.416 | 24.720 | 24.782 | 25.684 |
편차 | 0.599 | 0.363 | 0.442 | 0.283 | 0.183 | 0.221 | 0.321 | 0.362 | 0.170 | ||
대조구 | 고지방식이(HFD) | 평균 | 22.322 | 24.642 | 26.136 | 27.642 | 29.472 | 31.176 | 32.494 | 34.478 | 38.764 |
편차 | 0.666 | 0.741 | 0.754 | 0.775 | 0.945 | 0.938 | 0.803 | 1.344 | 1.468 | ||
실시예2-4-1 | DT7 (TauAlc 8.6+Cat 3+Bet 4) | 평균 | 20.834 | 22.456 | 22.744 | 24.094 | 25.884 | 27.388 | 29.236 | 29.638 | 31.662 |
편차 | 0.660 | 0.542 | 0.519 | 0.545 | 0.701 | 0.934 | 1.114 | 1.383 | 1.727 | ||
비교예2-5-1 | DT11 (Tau 8.6+Cat 3+Bet 4) | 평균 | 20.420 | 24.418 | 25.360 | 27.388 | 29.178 | 32.794 | 35.460 | 36.012 | 38.370 |
편차 | 0.353 | 0.498 | 0.608 | 0.630 | 0.853 | 0.843 | 1.101 | 0.950 | 0.771 | ||
대조구 | Metformin(MET) | 평균 | 21.105 | 23.550 | 23.608 | 25.125 | 25.705 | 27.198 | 28.355 | 27.368 | 29.343 |
편차 | 0.568 | 0.727 | 0.794 | 0.829 | 1.034 | 1.022 | 1.101 | 1.319 | 1.516 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 0.798 | 1.244 | 1.391 | 1.613 | 1.522 | 1.826 | 1.888 | 2.790 |
편차 | 0.444 | 0.473 | 0.475 | 0.448 | 0.507 | 0.504 | 0.499 | 0.517 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.320 | 3.814 | 5.320 | 7.150 | 8.854 | 10.172 | 12.156 | 16.442 |
편차 | 0.351 | 0.518 | 0.458 | 0.601 | 0.899 | 0.737 | 1.438 | 1.296 | ||
실시예2-4-1 | DT7 (TauAlc 8.6+Cat 3+Bet 4) | 평균 | 1.622 | 1.910 | 3.260 | 5.050 | 6.554 | 8.402 | 8.804 | 10.828 |
편차 | 0.251 | 0.200 | 0.259 | 0.269 | 0.334 | 0.486 | 0.733 | 1.120 | ||
비교예2-5-1 | DT11 (Tau 8.6+Cat 3+Bet 4) | 평균 | 3.998 | 4.940 | 6.968 | 8.758 | 12.374 | 15.040 | 15.592 | 17.950 |
편차 | 0.605 | 0.789 | 0.869 | 1.066 | 1.017 | 1.162 | 1.013 | 0.583 | ||
대조구 | Metformin(MET) | 평균 | 2.445 | 2.503 | 4.020 | 4.600 | 6.093 | 7.250 | 6.263 | 8.238 |
편차 | 0.442 | 0.383 | 0.637 | 0.910 | 0.795 | 1.090 | 0.944 | 1.090 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT7 | 0.1444 | 0.0090 | 0.0045 | 0.0128 | 0.0434 | 0.0799 | 0.0715 | 0.0112 |
HFD vs DT11 | 0.0433 | 0.2672 | 0.1320 | 0.2253 | 0.0320 | 0.0077 | 0.0865 | 0.3197 |
DT7 vs DT11 | 0.0067 | 0.0059 | 0.0035 | 0.0097 | 0.0006 | 0.0008 | 0.0006 | 0.0005 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 22.894 | 23.692 | 24.138 | 24.285 | 24.507 | 24.416 | 24.720 | 24.782 | 25.684 |
편차 | 0.599 | 0.363 | 0.442 | 0.283 | 0.183 | 0.221 | 0.321 | 0.362 | 0.170 | ||
대조구 | 고지방식이(HFD) | 평균 | 22.322 | 24.642 | 26.136 | 27.642 | 29.472 | 31.176 | 32.494 | 34.478 | 38.764 |
편차 | 0.666 | 0.741 | 0.754 | 0.775 | 0.945 | 0.938 | 0.803 | 1.344 | 1.468 | ||
실시예2-4-2 | DT10 (TauAlc 8.6+EGCG 1.5+Bet 4) | 평균 | 21.956 | 25.356 | 25.458 | 25.998 | 27.062 | 29.836 | 31.732 | 30.562 | 32.740 |
편차 | 0.483 | 0.640 | 0.524 | 0.740 | 0.666 | 0.811 | 0.946 | 0.975 | 1.135 | ||
비교예2-5-2 | DT14 (Tau 8.6+EGCG 1.5+Bet 4) | 평균 | 21.440 | 24.750 | 26.114 | 27.556 | 29.456 | 31.968 | 34.020 | 32.874 | 37.470 |
편차 | 0.638 | 0.998 | 1.142 | 1.400 | 1.654 | 2.005 | 2.181 | 2.012 | 2.186 | ||
대조구 | Metformin(MET) | 평균 | 21.105 | 23.550 | 23.608 | 25.125 | 25.705 | 27.198 | 28.355 | 27.368 | 29.343 |
편차 | 0.568 | 0.727 | 0.794 | 0.829 | 1.034 | 1.022 | 1.101 | 1.319 | 1.516 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 0.798 | 1.244 | 1.391 | 1.613 | 1.522 | 1.826 | 1.888 | 2.790 |
편차 | 0.444 | 0.473 | 0.475 | 0.448 | 0.507 | 0.504 | 0.499 | 0.517 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.320 | 3.814 | 5.320 | 7.150 | 8.854 | 10.172 | 12.156 | 16.442 |
편차 | 0.351 | 0.518 | 0.458 | 0.601 | 0.899 | 0.737 | 1.438 | 1.296 | ||
실시예2-4-2 | DT10 (TauAlc 8.6+EGCG 1.5+Bet 4) | 평균 | 3.400 | 3.502 | 4.042 | 5.106 | 7.880 | 9.776 | 8.606 | 10.784 |
편차 | 0.274 | 0.253 | 0.330 | 0.441 | 0.683 | 0.929 | 1.126 | 1.204 | ||
비교예2-5-2 | DT14 (Tau 8.6+EGCG 1.5+Bet 4) | 평균 | 3.310 | 4.674 | 6.116 | 8.016 | 10.528 | 12.580 | 11.434 | 16.030 |
편차 | 0.407 | 0.580 | 0.850 | 1.077 | 1.412 | 1.596 | 1.414 | 1.577 | ||
대조구 | Metformin(MET) | 평균 | 2.445 | 2.503 | 4.020 | 4.600 | 6.093 | 7.250 | 6.263 | 8.238 |
편차 | 0.442 | 0.383 | 0.637 | 0.910 | 0.795 | 1.090 | 0.944 | 1.090 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT10 | 0.0416 | 0.6033 | 0.0536 | 0.0254 | 0.4134 | 0.7471 | 0.0879 | 0.0126 |
HFD vs DT14 | 0.1029 | 0.3012 | 0.4338 | 0.5024 | 0.3467 | 0.2079 | 0.7296 | 0.8451 |
DT10 vs DT14 | 0.8592 | 0.1013 | 0.0526 | 0.0369 | 0.1299 | 0.1673 | 0.1564 | 0.0295 |
체중(g) | |||||||||||
구분 | 투여전 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | 25.706 | 25.614 | 27.006 | 26.814 | 28.744 | 29.442 | 29.258 | 29.476 | 27.442 |
편차 | 0.940 | 0.698 | 0.939 | 0.789 | 0.843 | 0.828 | 1.037 | 0.813 | 0.838 | ||
대조구 | 고지방식이(HFD) | 평균 | 24.920 | 27.448 | 29.878 | 34.452 | 36.850 | 38.748 | 40.524 | 43.686 | 42.344 |
편차 | 0.547 | 0.453 | 0.635 | 0.725 | 0.523 | 0.548 | 0.941 | 1.164 | 0.591 | ||
실시예2-5 | DT4 (TauAlc 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 25.422 | 27.170 | 30.180 | 32.488 | 33.968 | 35.218 | 36.214 | 38.048 | 36.188 |
편차 | 0.237 | 0.565 | 0.800 | 0.744 | 0.642 | 0.781 | 1.038 | 1.053 | 1.044 | ||
비교예2-6 | DT6 (Tau 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 23.088 | 26.216 | 29.082 | 32.910 | 32.922 | 38.018 | 39.414 | 40.820 | 40.618 |
편차 | 0.690 | 1.032 | 1.372 | 2.118 | 1.931 | 2.000 | 1.890 | 2.036 | 1.784 | ||
대조구 | Metformin(MET) | 평균 | 23.938 | 25.094 | 26.344 | 27.430 | 27.708 | 28.572 | 28.772 | 28.468 | 27.608 |
편차 | 0.612 | 0.551 | 0.792 | 0.710 | 0.915 | 0.853 | 0.784 | 0.836 | 0.979 |
체중 증가량(g) | ||||||||||
구분 | 1주 | 2주 | 3주 | 4주 | 5주 | 6주 | 7주 | 8주 | ||
대조구 | 정상식이(RD) | 평균 | -0.092 | 1.300 | 1.108 | 3.038 | 3.736 | 3.552 | 3.770 | 1.736 |
편차 | 0.325 | 0.259 | 0.270 | 0.414 | 0.339 | 0.389 | 0.333 | 0.369 | ||
대조구 | 고지방식이(HFD) | 평균 | 2.528 | 4.958 | 9.532 | 11.930 | 13.828 | 15.604 | 18.766 | 17.424 |
편차 | 0.326 | 0.461 | 0.473 | 0.440 | 0.960 | 1.156 | 1.228 | 0.689 | ||
실시예2-5 | DT4 (TauAlc 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 1.748 | 4.758 | 7.066 | 8.546 | 9.796 | 10.792 | 12.626 | 10.766 |
편차 | 0.372 | 0.625 | 0.580 | 0.465 | 0.589 | 0.835 | 0.846 | 0.849 | ||
비교예2-6 | DT6 (Tau 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 3.128 | 5.994 | 9.822 | 9.834 | 14.930 | 16.326 | 17.732 | 17.530 |
편차 | 0.619 | 0.933 | 1.724 | 1.487 | 1.526 | 1.382 | 1.553 | 1.357 | ||
대조구 | Metformin(MET) | 평균 | 1.156 | 2.406 | 3.492 | 3.770 | 4.634 | 4.834 | 4.530 | 3.670 |
편차 | 0.180 | 0.185 | 0.223 | 0.350 | 0.398 | 0.398 | 0.936 | 0.463 |
그룹 | 1 주 | 2 주 | 3 주 | 4 주 | 5 주 | 6 주 | 7 주 | 8 주 |
HFD vs DT4 | 0.1538 | 0.8033 | 0.0109 | 0.0007 | 0.0072 | 0.0097 | 0.0034 | 0.0003 |
HFD vs DT6 | 0.4161 | 0.3485 | 0.8751 | 0.2135 | 0.5580 | 0.6992 | 0.6156 | 0.9462 |
DT4 vs DT6 | 0.0924 | 0.3030 | 0.1682 | 0.4324 | 0.0138 | 0.0090 | 0.0203 | 0.0029 |
구분 | 혈당 (mg/dl) | 0분 | 30분 | 60분 | 90분 | 120분 | |
대조구 | 정상식이(RD) | 평균 | 123.60 | 328.60 | 324.00 | 235.60 | 151.20 |
편차 | 6.44 | 12.80 | 30.00 | 16.84 | 6.57 | ||
대조구 | 고지방식이(HFD) | 평균 | 188.70 | 479.70 | 461.60 | 458.40 | 250.10 |
편차 | 10.67 | 26.87 | 39.06 | 33.42 | 27.98 | ||
실시예 1-2(3) | DT15 (TauAlc) | 평균 | 121.25 | 335.25 | 295.25 | 193.75 | 126.25 |
편차 | 3.73 | 3.77 | 7.73 | 11.43 | 0.56 | ||
비교예 1-1 | DT19 (Tau) | 평균 | 111.80 | 298.00 | 295.60 | 189.40 | 119.00 |
편차 | 11.08 | 26.76 | 11.52 | 9.75 | 6.47 | ||
대조구 | Metformin(MET) | 평균 | 144.20 | 386.40 | 301.40 | 194.40 | 135.20 |
편차 | 15.92 | 17.73 | 24.43 | 21.21 | 17.23 |
그룹 | 투여전 | 30분후 | 60분후 | 90분후 | 120분후 |
HFD vs DT15 | 0.0023 | 0.0062 | 0.0224 | 0.0004 | 0.0182 |
HFD vs DT19 | 0.0006 | 0.0010 | 0.0119 | 0.0001 | 0.0065 |
DT15 vs DT19 | 0.4936 | 0.2625 | 0.9822 | 0.7904 | 0.3569 |
구분 | 혈당 (mg/dl) | 0분 | 30분 | 60분 | 90분 | 120분 | |
대조구 | 정상식이(RD) | 평균 | 123.60 | 328.60 | 324.00 | 235.60 | 151.20 |
편차 | 6.44 | 12.80 | 30.00 | 16.84 | 6.57 | ||
대조구 | 고지방식이(HFD) | 평균 | 188.70 | 479.70 | 461.60 | 458.40 | 250.10 |
편차 | 10.67 | 26.87 | 39.06 | 33.42 | 27.98 | ||
실시예 2-1 | DT16 (TauAlc 8.6+Ara 2.5) | 평균 | 117.00 | 289.20 | 302.20 | 196.20 | 121.40 |
편차 | 4.86 | 20.15 | 35.60 | 31.33 | 14.44 | ||
비교예2-3-2 | DT 18(Tau 8.6+Ara 2.5) | 평균 | 169.33 | 367.00 | 343.00 | 236.33 | 172.67 |
편차 | 9.21 | 22.27 | 32.94 | 28.55 | 23.62 | ||
대조구 | Metformin(MET) | 평균 | 144.20 | 386.40 | 301.40 | 194.40 | 135.20 |
편차 | 15.92 | 17.73 | 24.43 | 21.21 | 17.23 |
그룹 | 투여전 | 30분후 | 60분후 | 90분후 | 120분후 |
HFD vs DT16 | 0.0005 | 0.0005 | 0.0219 | 0.0003 | 0.0084 |
HFD vs DT18 | 0.3740 | 0.0549 | 0.1488 | 0.0060 | 0.1848 |
DT16 vs DT18 | 0.0029 | 0.0626 | 0.4990 | 0.4502 | 0.1322 |
구분 | 혈당 (mg/dl) | 0분 | 30분 | 60분 | 90분 | 120분 | |
대조구 | 정상식이(RD) | 평균 | 123.60 | 328.60 | 324.00 | 235.60 | 151.20 |
편차 | 6.44 | 12.80 | 30.00 | 16.84 | 6.57 | ||
대조구 | 고지방식이(HFD) | 평균 | 188.70 | 479.70 | 461.60 | 458.40 | 250.10 |
편차 | 10.67 | 26.87 | 39.06 | 33.42 | 27.98 | ||
실시예 2-1 | DT20 (TauAlc 8.6+Xyl 3.5) | 평균 | 115.00 | 306.40 | 330.40 | 240.40 | 142.80 |
편차 | 7.00 | 33.04 | 35.07 | 32.68 | 15.94 | ||
비교예2-3-2 | DT 21(Tau 8.6+Xyl 3.5) | 평균 | 134.20 | 340.60 | 331.40 | 240.40 | 155.40 |
편차 | 13.04 | 27.41 | 29.45 | 35.59 | 19.60 | ||
대조구 | Metformin(MET) | 평균 | 144.20 | 386.40 | 301.40 | 194.40 | 135.20 |
편차 | 15.92 | 17.73 | 24.43 | 21.21 | 17.23 |
그룹 | 투여전 | 30분후 | 60분후 | 90분후 | 120분후 |
HFD vs DT20 | 0.0005 | 0.0019 | 0.0513 | 0.0012 | 0.0233 |
HFD vs DT21 | 0.0089 | 0.0065 | 0.0483 | 0.0014 | 0.0440 |
DT20 vs DT21 | 0.2306 | 0.4486 | 0.9831 | 1.0000 | 0.6314 |
구분 | 혈당 (mg/dl) | 0분 | 30분 | 60분 | 90분 | 120분 | |
대조구 | 정상식이(RD) | 평균 | 120.60 | 392.80 | 296.00 | 203.20 | 158.60 |
편차 | 2.16 | 58.61 | 40.72 | 27.48 | 17.28 | ||
대조구 | 고지방식이(HFD) | 평균 | 210.80 | 528.20 | 527.40 | 448.80 | 342.20 |
편차 | 13.79 | 23.68 | 17.28 | 37.78 | 44.72 | ||
실시예2-5 | DT4 (TauAlc 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 121.20 | 418.75 | 347.25 | 265.25 | 182.75 |
편차 | 7.81 | 25.89 | 10.69 | 25.07 | 9.81 | ||
비교예2-6 | DT6 (Tau 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 199.60 | 505.80 | 471.40 | 417.40 | 318.40 |
편차 | 13.55 | 33.81 | 65.31 | 75.23 | 61.39 | ||
대조구 | Metformin(MET) | 평균 | 104.40 | 438.40 | 296.40 | 178.00 | 146.20 |
편차 | 3.72 | 8.68 | 23.15 | 14.35 | 3.02 |
그룹 | 투여전 | 30분 후 | 60분 후 | 90분 후 | 120분 후 |
HFD vs DT4 | 0.0005 | 0.0211 | 0.0001 | 0.0075 | 0.0176 |
HFD vs DT6 | 0.5783 | 0.6021 | 0.4312 | 0.7189 | 0.7620 |
DT4 vs DT6 | 0.0010 | 0.1003 | 0.1409 | 0.1303 | 0.0949 |
그룹 | 중성지방(㎎/㎗) | AST(IU/L) | ALT(IU/L) | ||
대조구 | 정상식이(RD) | 평균 | 76.02 | 91.34 | 10.85 |
표준편차 | 14.42 | 7.23 | 6.20 | ||
대조구 | 고지방식이(HFD) | 평균 | 148.78 | 129.70 | 24.71 |
표준편차 | 32.47 | 6.48 | 3.75 | ||
대조구 | Metformin(MET) | 평균 | 62.99 | 110.32 | 22.80 |
표준편차 | 10.70 | 16.00 | 7.16 | ||
실시예 1-2(3) | DT15 (TauAlc) | 평균 | 53.62 | 98.96 | 14.02 |
표준편차 | 7.22 | 6.11 | 3.82 | ||
비교예 1-1 | DT19 (Tau) | 평균 | 116.20 | 118.63 | 25.47 |
표준편차 | 13.34 | 12.02 | 8.60 |
그룹 | 중성지방 | AST | ALT |
HFD vs DT15 | 0.0383 | 0.0118 | 0.0890 |
HFD vs DT19 | 0.3805 | 0.4408 | 0.9372 |
DT15 vs DT19 | 0.0066 | 0.2211 | 0.3034 |
그룹 | 중성지방(㎎/㎗) | AST(IU/L) | ALT(IU/L) | ||
대조구 | 정상식이(RD) | 평균 | 76.02 | 91.34 | 10.85 |
표준편차 | 14.42 | 7.23 | 6.20 | ||
대조구 | 고지방식이(HFD) | 평균 | 148.78 | 129.70 | 24.71 |
표준편차 | 32.47 | 6.48 | 3.75 | ||
대조구 | Metformin(MET) | 평균 | 62.99 | 110.32 | 22.80 |
표준편차 | 10.70 | 16.00 | 7.16 | ||
실시예 2-1 | DT16 (TauAlc 8.6+Ara 2.5) | 평균 | 54.30 | 96.48 | 10.68 |
표준편차 | 8.66 | 3.52 | 4.15 | ||
비교예2-3-2 | DT 18(Tau 8.6+Ara 2.5) | 평균 | 66.97 | 94.51 | 7.02 |
표준편차 | 18.17 | 3.02 | 7.09 |
그룹 | 중성지방 | AST | ALT |
HFD vs DT16 | 0.0402 | 0.0042 | 0.0407 |
HFD vs DT18 | 0.1208 | 0.0076 | 0.0492 |
DT16 vs DT18 | 0.5202 | 0.7015 | 0.6546 |
그룹 | 중성지방(㎎/㎗) | AST(IU/L) | ALT(IU/L) | ||
대조구 | 정상식이(RD) | 평균 | 76.02 | 91.34 | 10.85 |
표준편차 | 14.42 | 7.23 | 6.20 | ||
대조구 | 고지방식이(HFD) | 평균 | 148.78 | 129.70 | 24.71 |
표준편차 | 32.47 | 6.48 | 3.75 | ||
대조구 | Metformin(MET) | 평균 | 62.99 | 110.32 | 22.80 |
표준편차 | 10.70 | 16.00 | 7.16 | ||
실시예 2-1 | DT20 (TauAlc 8.6+Xyl 3.5) | 평균 | 60.81 | 100.44 | 8.67 |
표준편차 | 23.96 | 8.57 | 3.04 | ||
비교예2-3-2 | DT 21(Tau 8.6+Xyl 3.5) | 평균 | 42.35 | 85.41 | 6.76 |
표준편차 | 5.26 | 2.97 | 0.71 |
그룹 | 중성지방 | AST | ALT |
HFD vs DT20 | 0.0609 | 0.0261 | 0.0105 |
HFD vs DT21 | 0.0120 | 0.0003 | 0.0015 |
DT20 vs DT21 | 0.4732 | 0.1363 | 0.5582 |
그룹 | 중성지방 | AST(IU/L) | ALT(IU/L) | ||
대조구 | 정상식이(RD) | 평균 | 113.61 | 10.30 | 5.32 |
표준편차 | 22.21 | 1.41 | 0.33 | ||
대조구 | 고지방식이(HFD) | 평균 | 135.37 | 21.60 | 13.31 |
표준편차 | 22.74 | 4.33 | 3.96 | ||
대조구 | Metformin(MET) | 평균 | 107.14 | 16.06 | 8.05 |
표준편차 | 10.29 | 0.99 | 0.72 | ||
실시예2-4-1 | DT7 (TauAlc 8.6+Cat 3+Bet 4) | 평균 | 100.68 | 11.41 | 7.01 |
표준편차 | 7.23 | 1.71 | 1.07 |
그룹 | 중성지방 | AST | ALT |
HFD vs DT7 | 0.451 | 0.071 | 0.176 |
그룹 | 중성지방 | AST(IU/L) | ALT(IU/L) | ||
대조구 | 정상식이(RD) | 평균 | 81.39 | 10.09 | 0.99 |
표준편차 | 17.61 | 3.35 | 0.38 | ||
대조구 | 고지방식이(HFD) | 평균 | 133.80 | 26.92 | 14.79 |
표준편차 | 8.13 | 4.44 | 5.31 | ||
대조구 | Metformin(MET) | 평균 | 46.75 | 14.10 | 3.50 |
표준편차 | 16.82 | 5.08 | 1.20 | ||
실시예2-5 | DT4 (TauAlc 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 59.85 | 13.52 | 1.03 |
표준편차 | 7.61 | 2.66 | 0.43 | ||
비교예2-6 | DT6 (Tau 8.6+EGCG 1.5+Bet 4+Xyl 3.5) | 평균 | 86.72 | 14.10 | 11.22 |
표준편차 | 17.42 | 5.08 | 4.19 |
그룹 | 중성지방 | AST | ALT |
HFD vs DT4 | 0.003 | 0.0465 | 0.0565 |
HFD vs DT6 | 0.0386 | 0.0940 | 0.6119 |
DT4 vs DT6 | 0.2458 | 0.9284 | 0.0695 |
Claims (23)
- 제 1 극성 용매상에서 타우린을 가온하면서 용해시키고, 제 2 극성 용매를 첨가하여 생성된 변성 타우린으로써,제 1 용매와 제 2 용매간 극성도의 차이가 5이하이고,라만 스펙트럼상의 위치 847, 891, 1182, 1256, 1427, 1458㎝-1 에서 847/891의 흡수대 비율, 1182/1256 흡수대 비율, 및 1427/1458 흡수대 비율이 모두 1 미만인 변성 타우린.
- 제 1항에 있어서,변성 타우린이 녹기 시작하는 점(onset point)은 330도 내지 340도인 변성 타우린.
- 제 1항에 있어서,수용해도는 75 내지 79g/L인 변성 타우린.
- 제 1항에 있어서,상기 변성 타우린은 적외선분광(FT-IR)에서 1650 내지 2800㎝-1 위치의 흡수 파장이 타우린과 상이한 변성 타우린.
- 제 1항에 있어서,제 1 극성 용매는 물이고, 제 2 극성 용매는 메틸기(-CH3)를 포함하는 극성 용매인, 변성 타우린.
- 제 5항에 있어서,제 2 극성 용매는 메탄올, 에탄올, 부탄올, 아세트산, 아세톤, 프로판올, 클로로포름, 및 에틸아세테이트로 구성된 군으로부터 선택된 어느 하나인 변성 타우린.
- 제 1항 내지 제 6항중 어느 한 항의 변성 타우린을 유효성분으로 포함하는 대사질환 예방 또는 치료용 약학조성물.
- 제 7항에 있어서,상기 대사질환은 당뇨병, 비만 또는 혈전성 질환인, 약학조성물.
- 제 8항에 있어서,상기 혈전성 질환은 심근 경색증, 허혈성 뇌졸중, 출혈성 뇌졸중, 폐 혈전증, 심부정맥 혈전증, 말초 혈관 폐쇄증, 심부정맥 혈전증, 간문맥 혈전증, 신장정맥 폐쇄증, 뇌 정맥동 혈전증, 말초 신경질환증, 말초 혈관성 질환증, 신증 및 중심 망막혈관 폐쇄증으로 구성되는 그룹으로부터 선택된 어느 하나 이상인, 약학조성물.
- 제 7항에 있어서,당, 폴리페놀 및 아미노산으로 구성되는 그룹으로부터 선택된 어느 하나 이상을 추가로 포함하는, 약학조성물.
- 제 10항에 있어서,상기 당은 케토트리오스, 알도트리오스, 케토테트로스, 알도테트로스, 리불로오스, 자일로오스, 리보오스, 아라비노오스, 만노오스, 프락토오스, 글루코오스, 슈크로오즈, 락토오즈, 말토오즈, 트레할로즈, 이눌린, 및 셀룰로오스로 구성되는 그룹으로부터 선택된 어느 하나 이상인, 약학조성물.
- 제 10항에 있어서,상기 폴리페놀은 플라바놀(flavanol), 플라본(flavone), 이소플라본(isoflavone), 플라보놀(flavonol), 플라바논(flavanone), 안토시아닌(anthocyanin), 오론(aurone), 칼콘(chalcone), 디히드로칼콘(dihydrochalcone) 및 이들의 유도체로 구성되는 그룹으로부터 선택된 어느 하나 이상인, 약학조성물.
- 제 10항에 있어서,상기 아미노산은 베타인, 글리신, 오르니틴, 프롤린, 디메틸글리신, 아스파르트산, 글루탐산, 류신 및 메티오닌으로 구성되는 그룹으로부터 선택된 어느 하나 이상인, 약학조성물.
- 제 10항에 있어서,상기 타우린과 당의 몰비는 0.1 내지 3.5 : 0.01 내지 3.5인, 약학조성물.
- 제 10항에 있어서,상기 타우린과 폴리페놀의 몰비는 0.1 내지 3.5 : 0.001 내지 3.5인, 약학조성물.
- 제 10항에 있어서,상기 타우린과 아미노산의 몰비는 0.1 내지 3.5 : 0.01 내지 3.5인, 약학조성물.
- 제 1 극성 용매상에서 타우린을 가온하면서 용해시키는 단계 및제 2 극성 용매를 첨가하여 변성 타우린을 생성시키는 단계를 포함하고,제 1 용매와 제 2 용매간 극성도의 차이가 5이하이며,제 1 극성 용매는 물이고, 제 2 극성 용매는 메틸기(-CH3)를 포함하는 극성 용매인, 변성 타우린을 제조하는 방법.
- 제 17항에 있어서,제 2 극성 용매는 메탄올, 에탄올, 부탄올, 아세트산, 아세톤, 프로판올, 클로로포름, 및 에틸아세테이트로 구성된 군으로부터 선택된 어느 하나인 변성 타우린을 제조하는 방법.
- 제 17항에 있어서,라만 스펙트럼상의 위치 847, 891, 1182, 1256, 1427, 1458㎝-1 에서 847/891의 흡수대 비율, 1182/1256 흡수대 비율, 및 1427/1458 흡수대 비율이 모두 1 미만인 변성 타우린을 제조하는 방법.
- 제 17항에 있어서,변성 타우린이 녹기 시작하는 점(onset point)은 330도 내지 340도인 변성 타우린을 제조하는 방법.
- 제 17항에 있어서,수용해도는 75 내지 79g/L인 변성 타우린을 제조하는 방법.
- 제 17항에 있어서,상기 변성 타우린은 적외선분광(FT-IR)에서 1650 내지 2800㎝-1 위치의 흡수 파장이 타우린과 상이한 변성 타우린을 제조하는 방법.
- 제 1항 내지 제 6항 중 어느 한 항의 변성 타우린을 포함하는 대사질환 개선 및 완화용 식품조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/535,212 US20170340584A1 (en) | 2014-12-16 | 2015-12-16 | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same |
JP2017531991A JP2018502074A (ja) | 2014-12-16 | 2015-12-16 | 変性タウリン及びそれを含む代謝疾患予防または治療用薬学組成物 |
CN201580068319.0A CN106999455A (zh) | 2014-12-16 | 2015-12-16 | 改性牛磺酸以及含有改性牛磺酸的用于预防或治疗代谢疾病的药物组合物 |
EP15870313.2A EP3235808A4 (en) | 2014-12-16 | 2015-12-16 | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same |
US15/414,322 US9877938B2 (en) | 2014-12-16 | 2017-01-24 | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0181652 | 2014-12-16 | ||
KR20140181652 | 2014-12-16 | ||
KR10-2015-0000781 | 2015-01-05 | ||
KR20150000781 | 2015-01-05 | ||
KR10-2015-0048106 | 2015-04-04 | ||
KR20150048106 | 2015-04-06 | ||
KR10-2015-0108672 | 2015-07-31 | ||
KR20150108672 | 2015-07-31 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/414,322 Continuation US9877938B2 (en) | 2014-12-16 | 2017-01-24 | Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016099146A1 true WO2016099146A1 (ko) | 2016-06-23 |
Family
ID=56126945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/013789 WO2016099146A1 (ko) | 2014-12-16 | 2015-12-16 | 변성 타우린 및 이를 포함하는 대사질환 예방 또는 치료용 약학조성물 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20170340584A1 (ko) |
EP (1) | EP3235808A4 (ko) |
JP (1) | JP2018502074A (ko) |
KR (2) | KR101666907B1 (ko) |
CN (1) | CN106999455A (ko) |
WO (1) | WO2016099146A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473612A4 (en) * | 2016-06-15 | 2020-01-22 | Byun, Jonghyun | MODIFIED TAURINE AND PREPARATION METHOD THEREOF |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210043909A (ko) | 2019-10-14 | 2021-04-22 | (주)아이에스엘 | 도광판 |
WO2023199995A1 (ja) * | 2022-04-15 | 2023-10-19 | コスメディ製薬株式会社 | タウリンの微細針状又は柱状結晶を配合した皮膚外用剤組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000119179A (ja) * | 1998-10-09 | 2000-04-25 | Taisho Pharmaceut Co Ltd | インスリン非依存性糖尿病の合併症の予防薬 |
JP2005527234A (ja) * | 2002-05-31 | 2005-09-15 | スオメン・ラビットセムスインスティトゥーティ・オイ | 飲料組成物及び飲料の製造方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444694A (en) * | 1983-04-22 | 1984-04-24 | The Dow Chemical Company | Preparation of 2-aminoalkanesulfonic acid |
JP3080801B2 (ja) * | 1992-12-25 | 2000-08-28 | 三井化学株式会社 | タウリンの精製法 |
JPH0717943A (ja) * | 1993-07-02 | 1995-01-20 | Mitsui Toatsu Chem Inc | タウリンの精製法 |
AU2001278197A1 (en) | 2000-07-28 | 2002-02-13 | Bioenergy Inc. | Compositions and methods for improving cardiovascular function |
JP3819000B2 (ja) * | 2003-12-17 | 2006-09-06 | 日本クリニック株式会社 | タウリンの抽出方法 |
JP4495481B2 (ja) * | 2004-02-18 | 2010-07-07 | イーグル・エンジニアリング・エアロスペース株式会社 | シール装置 |
KR101132175B1 (ko) * | 2005-08-24 | 2012-04-05 | 이화여자대학교 산학협력단 | 타우린과 환원당을 이용한 2-메톡시-5(또는 6)-메틸피라진의 제조방법 |
KR101121543B1 (ko) | 2007-07-04 | 2012-03-06 | 학교법인 선목학원 | 벼과식물로부터 수득되는 전분 또는 식이섬유를 포함하는허혈성 질환 및 퇴행성 뇌질환의 예방 및 치료를 위한조성물 |
KR101190953B1 (ko) * | 2009-08-25 | 2012-10-12 | 한올바이오파마주식회사 | 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
CN102241690B (zh) | 2010-05-13 | 2015-08-12 | 天津药物研究院 | 一类含腈基的噻吩并吡啶酯类衍生物、其制备方法和用途 |
KR101412221B1 (ko) * | 2012-08-14 | 2014-06-27 | (주)바이오뉴트리젠 | 구기자잎 추출 분말과 베타인을 유효성분으로 함유하는 항비만 조성물 |
-
2015
- 2015-12-16 CN CN201580068319.0A patent/CN106999455A/zh active Pending
- 2015-12-16 WO PCT/KR2015/013789 patent/WO2016099146A1/ko active Application Filing
- 2015-12-16 EP EP15870313.2A patent/EP3235808A4/en not_active Withdrawn
- 2015-12-16 JP JP2017531991A patent/JP2018502074A/ja active Pending
- 2015-12-16 KR KR1020150179902A patent/KR101666907B1/ko active IP Right Review Request
- 2015-12-16 US US15/535,212 patent/US20170340584A1/en not_active Abandoned
-
2016
- 2016-09-29 KR KR1020160125653A patent/KR102029449B1/ko active IP Right Grant
-
2017
- 2017-01-24 US US15/414,322 patent/US9877938B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000119179A (ja) * | 1998-10-09 | 2000-04-25 | Taisho Pharmaceut Co Ltd | インスリン非依存性糖尿病の合併症の予防薬 |
JP2005527234A (ja) * | 2002-05-31 | 2005-09-15 | スオメン・ラビットセムスインスティトゥーティ・オイ | 飲料組成物及び飲料の製造方法 |
Non-Patent Citations (3)
Title |
---|
CHO, HYE JEONG ET AL.: "Anti-Adipogenic Effect of Taurine-Carbohydrate Derivatives", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 35, no. 6, June 2014 (2014-06-01), pages 1863 - 1866, XP055450110 * |
See also references of EP3235808A4 * |
YANG, JIAO ET AL.: "Determination and Correlation of the Solubility for Taurine in Water and Organic Solvent Systems", JOURNAL OF CHEMICAL & ENGINEERING DATA, vol. 55, 23 April 2010 (2010-04-23), pages 2620 - 2623, XP055450109 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3473612A4 (en) * | 2016-06-15 | 2020-01-22 | Byun, Jonghyun | MODIFIED TAURINE AND PREPARATION METHOD THEREOF |
Also Published As
Publication number | Publication date |
---|---|
JP2018502074A (ja) | 2018-01-25 |
KR20160119013A (ko) | 2016-10-12 |
CN106999455A (zh) | 2017-08-01 |
EP3235808A4 (en) | 2018-07-04 |
US9877938B2 (en) | 2018-01-30 |
KR102029449B1 (ko) | 2019-10-07 |
EP3235808A1 (en) | 2017-10-25 |
KR20160073332A (ko) | 2016-06-24 |
US20170165211A1 (en) | 2017-06-15 |
US20170340584A1 (en) | 2017-11-30 |
KR101666907B1 (ko) | 2016-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013176512A1 (en) | Panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation, a method of preparing the panax spp. plant extract, and a composition including the panax spp. plant extract | |
WO2016099146A1 (ko) | 변성 타우린 및 이를 포함하는 대사질환 예방 또는 치료용 약학조성물 | |
WO2017030410A1 (ko) | 검정콩잎 추출물 및 이로부터 분리한 플라보놀배당체를 유효성분으로 함유하는 대사증후군의 예방 또는 치료용, 또는 항산화용 조성물 | |
WO2022035115A1 (ko) | 오리나무 추출물 또는 이로부터 분리된 화합물을 함유하는 골격근 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2012067316A1 (ko) | 테로카판계 화합물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 대사성 질환 또는 이들의 합병증의 예방 또는 치료용, 또는 항산화용 조성물 | |
WO2010079914A2 (en) | A composition comprising the compound isolated from the extract of rubiae radix for preventing and treating inflammatory diseases | |
WO2020071667A1 (ko) | 몰로키아 추출물을 유효성분으로 하는 장내 균총 개선용 조성물, 또는 장내 염증, 장누수증후군, 비만 또는 대사성질환 개선, 예방 또는 치료용 조성물 | |
WO2014007447A1 (ko) | 하이드록시 챨콘 화합물을 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 조성물 | |
WO2022005201A1 (ko) | 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물 | |
WO2010090498A2 (ko) | 이고들빼기 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
WO2017217757A1 (ko) | 변성 타우린 및 이의 제조방법 | |
WO2012093787A2 (ko) | 플로로글루시놀, 플로로탄닌 또는 갈조류 추출물을 포함하는 가바 a형-벤조다이아제핀 수용체 활성용 조성물 및 불안 완화, 경련 개선, 진정 작용, 및 수면 유도 및 개선용 조성물 | |
WO2010041908A2 (ko) | 판두라틴 유도체 또는 보에센베르기아 판두라타 추출물의 신규한 용도 | |
WO2019045467A2 (ko) | 항산화 및 항고혈압 효과를 가지는 광어 연육 및 이의 제조방법 | |
WO2021206455A1 (ko) | 멜리사엽 분획 추출물 및 이를 포함하는 신규한 약학적 조성물 | |
WO2012138146A9 (ko) | 돌콩의 열처리분말 또는 추출물을 유효성분으로 하는 당뇨병 및 당뇨합병증의 예방 및 치료를 위한 조성물 | |
WO2014168413A1 (en) | The composition comprising a purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom, as an active ingredient for preventing or treating chronic obstructive pulmonary disease and the use thereof | |
WO2015046743A1 (ko) | 댕댕이나무 열매 추출물을 유효성분으로 포함하는 갑상선 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019139365A1 (ko) | 신규한 페닐설포닐 옥사졸 유도체 및 이의 용도 | |
WO2018217009A1 (ko) | 신선초 추출물 또는 이로부터 분리된 화합물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2022092461A1 (ko) | 비만 또는 당뇨의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
WO2019039810A1 (ko) | 댕댕이나무 추출물을 포함하는 통증의 예방 또는 치료용 조성물 | |
WO2011081231A1 (ko) | 호장근 부탄올 분획물 또는 에칠아세테이트 분획물을 이용한 비만 치료 및 예방용 조성물과 기능성 식품 | |
WO2023136668A1 (ko) | 돌외잎 추출물을 유효성분으로 포함하는 운동수행능력 향상용 조성물 | |
WO2017192013A1 (ko) | 팥을 포함하는 근 기능 개선 또는 운동수행능력 향상용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15870313 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017531991 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15535212 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015870313 Country of ref document: EP |